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HDAC4 INTEGRATES PTH AND SYMPATHETIC SIGNALING IN 
OSTEOBLASTS 
Munevver Parla Makinistoglu 
 
Both parathyroid hormone (PTH) and the sympathetic tone promote Rankl expression in osteoblasts and 
osteoclast differentiation by enhancing cAMP production, through an unidentified transcription factor for 
PTH and ATF4 for the sympathetic tone. How two extracellular cues using the same second messenger 
in the same cell elicit different transcriptional events is unknown. Here we show that PTH favors Rankl 
expression by triggering the ubiquitination of HDAC4, a class II histone deacetylase, partly via Smurf2. 
HDAC4 degradation releases MEF2c that transactivates the Rankl promoter. On the other hand, 
sympathetic signaling in osteoblasts favors the accumulation of HDAC4 and its association with ATF4. In 
this setting, HDAC4 increases Rankl expression. Through this interaction with ATF4, HDAC4 also 
influences Osteocalcin expression, and its endocrine and cognitive functions. This study shows that 
through its ability to differently connect distinct extracellular cues to their genome, HDAC4 is a global 
regulator of osteoblast functions.  
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1. Global Regulation Of Gene Expression By Modifications Of Chromatin 
Structure 
Cell to cell differences in eukaryotes are determined by the expression of different sets of genes. 
The bases of these differences, in part, lay in the organization of the genetic material into a structure 
called chromatin. Chromatin contains the genetic information wrapped around a complex of histone and 
non-histone proteins. This basic repeating unit of chromatin is called the nucleosome. The nucleosome 
consists of an octamer of core proteins that includes 4 histone partners; an H3-H4 tetramer and two H2A-
H2B dimers, which are wrapped with two superhelical turns of DNA. Histones are small basic proteins 
with a globular domain and a flexible and charged NH2-terminus (histone tail) that protrudes from the 
nucleosome and that is subjected to post-translational modifications (Kornberg 1974; Oudet et al. 1975). 
The structure of chromatin has been central to the thinking that it plays an important regulatory 
role and that multiple signaling pathways converge on histones. In 1928, E. Hertz discovered that there 
are two forms of chromatin that differs in their degree of condensation, the heterochromatin and the 
euchromatin (Passarge 1979). In general, many inactive genes lay in the heterochromatin (Grewal and 
Jia 2007).  There are two types of heterochromatin; the constitutive heterochromatin, which is silenced 
and highly condensed, and the facultative heterochromatin, which could be regulated by cellular signals 
(Birchler et al. 2000; Trojer and Reinberg 2007).  
On the other hand, euchromatin, the relaxed form of chromatin that allows transcriptional activity, 
contains many genes. The relaxed structure of the euchromatin is due to two post-translational 
modifications of the histone proteins, methylation and acetylation (Grunstein 1997; Santos-Rosa et al. 
2002). These modifications allow specific cellular machinery, such as RNA polymerase 2 to enter the 
structure and transcribe functional mRNA. The presence of these two forms of chromatin was the first 
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i. Modifications of Chromatin Structure 
In order to render the genetic information available, eukaryotes have developed mechanisms to 
modulate the structure of their chromatin. One of the modifications of chromatin structure is via DNA 
methylation.  
DNA methylation is a covalent modification of the DNA. Prokaryotes use DNA methylation on 
cytosine or adenosine bases to protect the DNA from mutations that could occur during replication 
(Bestor 1990). Instead in eukaryotes, methylation is specific to the cytosine bases in the context of CpG 
islands that are distributed across the genome, with the exception of certain regions (Bird 1986). In 
general, methylation of these regions by DNA methyltransferases (Dnmts) in plants and mammals results 
in the repression of the transcriptional activity. For example, inactivation of the X chromosome is due to 
methylation of certain CpG islands, creating a global repression of this chromosome (Bestor 1990; Goll 
and Bestor 2005).  
Aside from DNA methylation, the post-translational modifications of the histone tails also play a 
large role in regulating chromatin structure. These modifications of the histone tails include: 
i. Methylation on Lysine or Arginine residues 
ii. Acetylation and Deacetylation 
iii. Phosphorylation 
iv. Ubiquitination 
Given that the work described in this thesis focuses on a class of histone deacetylases (HDACs), 
the next sections will discuss in detail the regulation of gene expression by histone acetylation and 
deacetylation.  
ii. Histone acetylation and deacetylation 
One of the first modifications of histones reported, acetylation, was discovered almost 60 years 
ago.  Acetylation is a reversible post-translational modification characterized by the addition of acetyl 
groups to the lysines at the histone-tails.  Histone acetylation is a hallmark of the transcriptionally active 
parts of chromatin (Grunstein 1997). Several experiments demonstrated that the time course of histone 
acetylation resembles closely to that of RNA synthesis, and that higher the acetylation on the histones, 
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the lower the inhibition was on the RNA polymerase action (Allfrey and Mirsky 1964). However, it was 
initially unclear whether histone acetylation was a cause or an effect of increased transcription. 
As a part of the regulation of RNA synthesis, acetylation is a reversible process as the newly 
synthesized histones are deacetylated upon their deposition, a modification that negatively affects 
transcription. Acetylation of histones is carried out by histone acetyltransferases (HATs), and their action 
is reversed by histone deacetylases (HDACs). Identification of these enzymes shed further light on the 
mechanistic regulation and functions of the histones (Bannister and Kouzarides 2011).  
a. HATs 
HATs are grouped into two classes depending on their cellular origins and functions. B-type HATs 
(HAT-Bs) are cytoplasmic that are responsible for catalyzing acetylation during the transport of newly 
synthesized histones from cytoplasm to the nucleus for deposition onto the newly replicated DNA (Wolffe 
1992). 
In contrast, A-type HATs are nuclear and more likely to be involved in the transcription related 
acetylation events. The first catalytic subunit of A-type HAT, p55, was identified through macromolecular 
preparations of a ciliated protozoan in gel-activity assays. This finding surprisingly revealed that this 
ciliate enzyme shows sequence similarities to a transcriptional regulator previously identified in yeast, 
Gcn5. This discovery provided strong molecular evidence that histone acetylation and transcriptional 
regulation are closely linked (Roth et al. 2001). Further studies led to the identification of other co-
activators or transcriptional adaptors with intrinsic HAT activity, including mammalian GCN5 and its 
ortholog, PCAF, CREB-binding protein (CBP), p300, and TAFII250 (Kuo and Allis 1998). 
  Therefore, given the importance of histone acetylation in gene activation, it is no surprise that 
HAT activity would be strictly regulated as gene expression programs are rapidly changing (Brownell and 
Allis 1996). 
b. HDACs 
Histone deacetylases (HDACs) inhibit transcription in part by removing acetyl groups from lysine 
residues at the histone tails (Wolffe 1996; Marks et al. 2001). Over the years, the use of HDAC inhibitors 
from the simplest chemical, butyric acid, to more complicated inhibitors of bacterial or fungal origin, 
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tropoxin B or Trichostatin A (TSA) respectively, have been proven to be instrumental in studying histone 
acetylation. These studies made it clearer that HDACs not only act on histones but they have a variety of 
cellular substrates. Especially, as it will be discussed further in detail, Class IIa HDACs posses a weak 
deacetylase activity despite of their highly conserved deacetylase domain, suggesting the importance of 
other cellular substrates for their actions (Hassig et al. 1997; Marks et al. 2001). 
HDACs, in general, lack DNA-binding ability and are dependent on their interaction with 
transcriptional activators or repressors as well as multi-protein transcriptional complexes for their 
recruitment to target genes. HDACs are highly conserved enzymes dating back to prokaryotes. The first 
HDAC, HDAC1, was identified due to its 60% similarity in the protein sequences with the yeast 
transcriptional repressor Rpd3p, suggesting a direct role in gene regulation (Vidal and Gaber 1991; 
Taunton et al. 1996). Since the identification of the first HDAC, further identified mammalian HDACs are 
divided into four families, Class I, Class IIa, Class IIb, and Class IV HDACs, which are referred as 
classical HDACs that are zinc-dependent deacetylases. In addition to these classical HDACs, another 
group of deacetylases that are dependent on nicotine adenine dinucleotide (NAD+) for their catalytic 
activity and that show no sequence similarity to classical HDACs is the sirtuins that are also referred as 
Class III HDACs (Gray and Ekstrom 2001; Marks et al. 2001; Verdin et al. 2003; Haberland et al. 2009). 
The rest of this section will focus on class II HDACs.  
Class II HDACs (HDAC4, 5, 6, 7, 9 and 10): 
Class II HDACs are related to yeast protein HDA1, and taxonomic studies based on the 
homology within the catalytic domain have identified these enzymes in all eukaryotes as well as in the 
majority of the prokaryotic organisms. This class of HDACs is further subdivided into two groups, Class IIa 
HDACs (HDAC4, 5, 7, and 9) and Class IIb HDACs (HDAC6 and HDAC10) based on their sequence 
homology and domain organization. Class IIa HDACs unlike the class itself are only found in metazoans 
and especially these four members of this family are unique to vertebrates (HDAC4, 5, 7, and 9) (Verdin 
et al. 2003; Haberland et al. 2009). 
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Class IIa HDACs (HDAC4, 5, 7 and 9): 
Class IIa HDACs are preferentially expressed in certain cell types. For example, HDAC4, 5 and 9 
are particularly well expressed in brain, skeletal muscle and heart. HDAC4, in addition, shows robust 
expression in skeletal growth plates. The expression of HDAC7, on the other hand, is mostly restricted to 
endothelial cells and thymocytes (Zhang et al. 2002; Chang et al. 2004; Vega et al. 2004; Chang et al. 
2006). 
The structure of these HDACs consists a large N-terminal extension with conserved binding sites 
for transcription factors such as Myocyte Enhancer Factor 2 (MEF2) as further discussed in the next 
chapter. These transcription factors have been reported by several studies to be regulated by class II 
HDACs in various tissues. In addition to their N-terminal domain, this class of HDACs also possesses a 
highly conserved, catalytically inactive HDAC domain. One example of this is MEF2-interacting 
transcription repressor (MITR), which is a splice variant of HDAC9 that has been shown to inhibit MEF2 
target genes, despite lacking the HDAC catalytic domain (Zhang et al. 2001a; Zhang et al. 2001b). Class 
II HDACs also consist conserved serine residues residing at their regulatory N-terminal region in addition 
to a nuclear localization signal (NLS) and a nuclear export signal (NES) within their structure. 
Phosphorylation of these conserved serine residues promote the binding of a chaperon protein, 14-3-3, 
allowing their shuttling between nucleus and cytoplasm. Therefore, this unique structure of class IIa 
HDACs that allows their regulation via phosphorylation, provides evidence for the regulation of 
transcription via extracellular signals (Fischle et al. 2001; Verdin et al. 2003; Haberland et al. 2009). 
Class IIa HDACs have also been shown to recruit Class I HDACs through their C-terminal domain 
as one of the mechanisms of their repressive action. In addition, they could interact with other 
transcriptional repressors like heterochromatin protein (HP1), and C-terminal binding protein (CTBP) 
through their regulatory N-terminal domain. The use of mouse genetics has been instrumental in further 
understanding the function of this class of HDACs in vivo. Although each gene displays a tissue-specific 
expression regulating specific programs, it was also observed that they share commonalities in their 
function, pointing out similar mechanisms of action (Verdin et al. 2003; Haberland et al. 2009). 
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i. HDAC4 
HDAC4 importance during skeletogenesis was revealed with the deletion of this gene in mice 
(Vega et al. 2004). Histological analyses of the bones of Hdac4-/- mice demonstrated that these mice 
have increased, immature ossification of their bones, which could also explain the perinatal lethality of 
these mice. As most of their ribs are formed from mineralized bone, this prevents the expansion of the 
ribs and therefore proper breathing. Another striking feature of this phenotype was the similarities 
between the skeletal abnormalities observed in these mice compared to those observed in mice 
overexpressing Runx2, a transcription factor expressed in proliferating chondrocytes promoting 
chondrocyte differentiation. Further analysis of the mice supported by the molecular data demonstrated 
that HDAC4 interacts with and inhibits Runx2 activity in chondrocytes, therefore leading to immature 
endochondral bone formation (Vega et al. 2004). Through the studies performed in chick chondrocytes, 
HDAC4 was also demonstrated to inhibit chondrocyte hypertrophy downstream of parathyroid hormone-
related peptide (PTHrP) signaling by inhibiting MEF2c function in chondrocytes (Kozhemyakina et al. 
2009). In addition, through its association with HDAC5, HDAC4 was also shown to regulate muscle 
differentiation (McKinsey et al. 2000). 
ii. HDAC5 and HDAC9 
With the use of mouse genetics, HDAC5 and 9 have been shown to have redundant functions in 
inhibiting the cardiac growth upon stress. Mice with the deletion of either Hdac5 or Hdac9 are viable 
(McKinsey et al. 2000; Zhang et al. 2002), however the compound mutant mice lacking both of these 
genes die due to ventricular septal defects and thin-walled myocardium which are caused by 
abnormalities in the growth and maturation of cardiomyocytes (Chang et al. 2004). Upon stress, adult 
heart responds in a pathological growth response that ultimately causes loss of cardiac function. Mice 
lacking HDAC5 or HDAC9 are hypersensitive to cardiac stress caused by excess workload or neuro-
humoral signaling. Given the known interaction of this class of HDACs with MEF2 family transcription 
factors as well as the importance of function of MEF2 proteins during cardiomyocyte differentiation further 
studies described that the cardiac defects observed in the compound mutant mice are a result of over 
activation of MEF2c transcription factor. In addition to their function during cardiac hypertrophy, HDAC5 
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and 9 along with HDAC4 have been shown to play a large role in skeletal muscle function, another tissue 
where these proteins are highly expressed (Potthoff et al. 2007).  
Skeletal muscles consist two different forms of fibers that have different contractility and 
metabolic functions. Slow-twitch or type1 myofibers are the highly vascularized fibers rich in mitochondria, 
exhibiting an oxidative metabolism and are resistant to fatigue, whereas fast-twitch or type II myofibers 
are involved in rapid bursts of contraction using a glycolytic metabolism and could fatigue rapidly. MEF2 
transcription factors are regulators of slow-twitch myofiber phenotype and this function of this family of 
transcription factors is inhibited by Class IIa HDACs. Deletion of either one of these Class IIa HDACs in 
skeletal muscle results in the conversion of type II fibers to type I fibers as the inhibition on MEF2 is 
released (Potthoff et al. 2007). 
In addition to these 2 functions, HDAC9 is also important in modulating the response of skeletal 
muscle to motor intervention. Electrical activity from the neurons represses the muscle specific gene 
expression such as those encoding the acetylcholine receptor subunits. Therefore, upon denervation, as 
the gene expression is repressed, muscle fibers become hypersensitive to acetylcholine. Deletion of 
HDAC9 in mice results in extreme sensitivity to changes in gene expression upon denervation, and 
overexpression of this gene results in an opposite phenotype where the skeletal muscles are rendered 
insensitive to denervation (Haberland et al. 2007). 
iii. HDAC7 
HDAC7 is specifically expressed in the endothelial cells in the inner lining of cardiovascular 
system. The deletion of Hdac7 in mice results in embryonic lethality due to loss of integrity between 
endothelial cells that eventually causes rapture of the blood vessels leading to hemorrhaging. This 
phenotype of these mice is accompanied with increased expression of matrix metalloproteinase 10 
(MMP10) that degrades the extracellular matrix perturbing the interactions of the endothelial cells with the 
smooth muscle cells. It was further shown that in mice lacking Hdac7, MEF2 activity is elevated to 
pathological levels. This function of HDAC7 in the regulation of MEF2 to maintain vascular integrity has 
important implications in various human disorders such as in vascular leakages observed in 
atherosclerosis and aneurysms (Chang et al. 2006). 
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Class IIb HDACs (HDAC6 and HDAC10): 
This subclass of class II HDACs is characterized by the presence of two HDAC catalytic domains, 
which is only a partial duplication in HDAC10. Similar to class IIa HDACs, this class of HDACs also shows 
some degree of specificity in their expression, such as HDAC6 is predominantly expressed in testes 
whereas expression of HDAC10 is seen in liver, spleen and kidney (Fischle et al. 2001). The analysis of 
the catalytic activity of two HDAC domains in HDAC6 with site-directed mutagenesis showed that these 
two domains might function independently from each other, however the separation of these domains 
from each other results in the loss of enzymatic activity (Grozinger et al. 1999). 
The use of HDAC inhibitors such as sodium butyrate or trapoxin showed that the enzymatic 
activity of HDAC6 and HDAC10 is more resistant to these inhibitors compared to that of both class I and 
class IIa HDACs. The sensitivity to both sodium butyrate and trapoxin is restored in HDAC10 when the 
second incomplete HDAC domain is removed suggesting that these two domains in HDAC10 might 
functionally interact (Furumai et al. 2001). 
Despite the use of a pharmacological nuclear export inhibitor on both HDAC6 and HDAC10, the 
cytoplasmic localization of these HDACs is not changed as it was shown for HDAC6 that its subcellular 
localization is dependent on a strong nuclear export signal (NES1) located within its N-terminal. For 
HDAC10, several putative export sequences have been reported however their true functionality is still 
under further investigation. 
Furthermore, HDAC6 was shown to act as a specific tubulin deacetylase mainly being localized 
with the microtubule network in the cytoplasm. It was also demonstrated that overexpression of HDAC6 
results in the chemotactic movement of the cells which is a process dependent on the microtubules 
(Zhang et al. 2008).  
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2. MEF2 Family Of MADS Box Family Transcription Factors 
MADS box is a conserved motif of 56 amino acids found within the DNA binding domain of 
various eukaryotic transcription factors. In general, MADS box is within the N-terminal of the protein. The 
four transcription factors that contain this conserved domain, MCM1 (Mini Chromosome Maintenance 1), 
AG (Agamous), DEFA (Deficiens) and SRF (Serum Response Factor), are the founder members of this 
family of transcription factors where the name itself is also derived from (Schwarz-Sommer et al. 1990). 
Myocyte Enhancer Factor 2 (MEF2) proteins, members of MADS box family of transcription 
factors, were initially cloned based on their sequence homology to SRF. This group of proteins was also 
referred as RSRFCs (Related to Serum Response Factor).  There is only one MEF2 gene in organisms 
like Saccharomyces cerevisiae, Drosophila and Caenorhabditis elegans whereas vertebrates have four 
MEF2 proteins identified, MEF2a, MEF2b, MEF2c, and MEF2d. MEF2 proteins were identified due to 
their binding through a conserved A+T rich region found in the promoters of muscle creatinine kinase 
(MCK) enhancer that was essential for full activity of the enhancer. Furthermore, MEF2 binding sites were 
found in the promoter regions of many muscle specific genes as they are the transcriptional activators for 
these genes (Shore and Sharrocks 1995). MEF2 DNA binding consensus sequence, YTA(A/T)4TAR,  is a 
distinct sequence that is only unique to MEF2 family transcription factors. MEF2A, C and D have different 
binding affinities to the same consensus sequence (Potthoff and Olson 2007).  
 MEF2 proteins share more than 80% amino acid homology within their MADS-box domain that is 
located within the amino terminal. Adjacent to this domain, they also contain a MEF2 domain, which is 
unique to this group of transcription factors. These two domains promote dimerization, DNA binding and 
co-factor interactions of these proteins. Although MEF2 proteins are transcriptional activators, for their 
functions they still rely on the recruitment of and cooperation with other transcription factors or co-
activators. The C-terminal of this family of transcription factors is the transcriptional activation domain, 
which is subjected to numerous alternative splicing, making it quite divergent between the members of 
this family (Potthoff and Olson 2007). 
MEF2 proteins have distinct as well as overlapping expression patterns. In vertebrates the 
highest expression of MEF2 proteins is observed in muscle and brain, however these proteins are also 
expressed in endothelium, lymphocytes, neural crest, smooth muscle and bone. Expression of MEF2 
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proteins in many cell types such as chondrocytes, neurons and muscle occur concurrently with the 
activation of several differentiation programs and it is the balance between the activating functions of the 
MEF2 proteins along with the repressive functions of Class IIa HDACs on these transcription factors that 
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3. Bone (Re)modelling  
Skeleton is a dynamic organ composed of two distinct tissues, cartilage and bone, and three 
specific cell types; chondrocytes in cartilage; osteoblasts and osteoclasts, which are the two major cell 
types in bone.  Among these cells, chondrocytes and osteoblasts share the same mesenchymal origin; 
being derived from osteo-chondro progenitors and are regulated by an elaborate transcriptional 
machinery to control and distinguish their differentiation, whereas, osteoclasts belong to monocyte/ 
macrophage lineage (Karsenty et al. 2009). 
In the last 20 to 30 years, many advances have been made in understanding the molecular bases 
of skeletal development and functions. In addition to a large cohort of transcription factors, mouse 
genetics has placed the skeleton in the center of diverse physiological network. This latter aspect is the 
focus of this thesis. 
In addition to expanding at a very slow rate during adulthood, bone is a dynamic organ that is 
continually remodeled. Bone (re)modeling is a lifetime process, during which mineralized bone is 
removed by osteoclasts, the bone resorbing cells, followed by formation of mineralized bone matrix by 
osteoblasts that are the bone forming cells.  
i. Osteoblasts and bone formation 
Osteoblasts, cells of mesenchymal origin, are multifunctional cells. They are responsible for 
synthesis of proteins of the bone matrix, osteoclast differentiation, and last but not least, they are the 
endocrine cells of the bone secreting two hormones, osteocalcin and FGF23 (Karsenty 1999; Fukumoto 
and Martin 2009; Karsenty and Ferron 2012).  
 Among the transcriptional machinery regulating osteoblast differentiation and function, Runx2, in 
addition to being a regulator of chondrocyte hypertrophy, is also the master gene of osteoblast 
differentiation (Ducy et al. 1997). Bone matrix consists mainly of type I collagen, which forms the 90% of 
its protein content. Runx2 also regulates the amount of bone matrix to be deposited by already 
differentiated osteoblasts, by promoting the expression of αI(I) collagen that consists a Runx2 binding site 
within its promoter (Ducy et al. 1997). Consistent with its function, mice lacking Runx2 have no 
osteoblasts, even though they have a normally patterned skeleton that is exclusively formed of cartilage 
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(Komori et al. 1997; Otto et al. 1997). Moreover, the mice with haploinsufficiency in the Runx2 locus, 
display delayed ossification of certain bones of the skull as well as hypoplastic clavicles (Otto et al. 1997).  
These abnormalities are similar to what is observed in a human skeletal dysplasia known as cleidocranial 
dysplasia (CCD).  The CCD patients are heterozygous for loss-of-function mutations in the Runx2 gene 
(Lee et al. 1997; Zhou et al. 1999).  
The differentiation of osteoblasts is also marked by the activation of an array of genes like 
alkaline phosphatase (ALP), type I collagen, bone sialoprotein (BSP) and Osteocalcin. Osteocalcin is the 
most abundant non-collagenous protein of bone and it is expressed only in differentiated osteoblasts 
marking the mature osteoblasts (Hauschka et al. 1989; Ducy et al. 1997; Karsenty 2008). 
Another transcription factor regulating bone formation by promoting osteoblast differentiation is 
ATF4 whose function is also implicated in a human disease, Coffin-Lowry syndrome (Yang et al. 2004). 
Deletion of Atf4 in mice results in delayed skeletal development and a severe decrease in bone mass due 
to a decrease in bone formation (Yang et al. 2004). At the molecular level, ATF4 binds to OSE1 site on 
the Osteocalcin promoter, thereby inducing Osteocalcin expression (Ducy and Karsenty 1995; Schinke 
and Karsenty 1999; Yang et al. 2004). ATF4 is also required for osteoblast function and bone formation in 
adult mice as it is necessary for the synthesis of type I collagen, a hallmark of the bone matrix, through its 
role in regulation of the amino acid transport (Yang et al. 2004). 
In addition to its function in bone formation and promoting Osteocalcin expression, ATF4 is also 
important for another function of osteoblasts. ATF4 induces the expression of Rankl (Receptor for 
activation of Nuclear Factor kappa B (NF-κΒ) (RANK) ligand), a molecule secreted by osteoblasts to 
promote osteoclast differentiation and thereby, bone resorption.  
ii. Osteoblasts and bone resorption 
In vitro experiments performed in 1990 demonstrated that maturation of macrophages to 
osteoclasts required the presence of marrow stromal cells or cells of the osteoblast progeny (Udagawa et 
al. 1990). This was due to osteoblasts secreting in addition to Rankl, another molecule, M-csf 
(Macrophage colony-stimulating factor) that are both necessary and sufficient for differentiation of 
osteoclasts (Udagawa et al. 1990). 
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Osteoclasts are the cells responsible for bone resorption. They are multinucleated cells formed by 
the fusion of mononuclear monocytes (Teitelbaum 2000). The initial experiments on mice with 
osteopetrosis, a disease characterized by an increase in bone mass due to a failure in the function of 
osteoclasts, demonstrated that injection of normal spleen cells in these mice corrected their bone 
phenotype, suggesting a hematopoietic origin for osteoclasts (Walker 1973).  Later on, the hematopoietic 
origin of osteoclasts was also established in humans (Coccia et al. 1980). 
What prompted the discovery of RANKL as an osteoclast differentiation factor is another 
molecule that is also secreted by osteoblasts, osteoprotegerin (OPG). OPG is the soluble decoy receptor 
for Rankl that competes with RANK receptor on osteoclast progenitors (Simonet et al. 1997). 
Overexpression of Opg results in osteopetrosis due to a decrease in bone resorption whereas the mouse 
models with deletion of Opg display a massive decrease in their bone mass due to an increase in bone 
resorption displaying severe osteoporosis (Simonet et al. 1997; Bucay et al. 1998; Mizuno et al. 1998).   
Bone resorption is a highly regulated multistep process, which includes the proliferation of 
immature osteoclast precursors, differentiation of these cells to osteoclasts and lastly the degradation of 
mineralized bone matrix by mature osteoclasts (FigureI. 2). Initial step of bone resorption is the 
attachment of osteoclasts to the target matrix. Bone is formed of type I collagen and non-collagenous 
proteins containing a mineral phase of substituted hydroxylapatite and initially the inorganic phase of 
bone desolubilizes which is followed by the degradation of the matrix (Blair et al. 1986). Osteoclasts 
achieve the demineralization of the bone by forming an acidified microenvironment called a resorption 
lacuna that is mediated by a vacuolar H+-adenosine triphosphatase (ATPase) (Blair et al. 1989). The pH 
of the resorption lacuna is maintained by an abundant proton transport via an energy independent Cl-
/HCO3- exchanger on the cell’s antiresorptive surface (Teti et al. 1989). Therefore the ion transporting in 
the resorptive microenvironment promotes a pH of approximately 4.5 (Silver et al. 1988). This acidic 
environment mobilizes the bone mineral, followed by the demineralized organic matter of bone being 
degraded by a lysosomal protease, cathepsin K and later being endocytosed by osteoclasts (Nesbitt and 
Horton 1997) (FigureI. 3). 
Given that bone remodeling is a continuous process necessary for maintenance of bone mass, 
osteoblasts maintain the balance between bone resorption and bone formation by balancing the 
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expression of Rankl and Opg that determines the amount of bone to be resorbed (Hofbauer 1999). Thus 
hormones and factors, which regulate Rankl expression in osteoblasts become of great importance in 
understanding the regulation of bone resorption (FigureI. 3). Such examples of major extracellular signals 
that are known to induce Rankl expression in osteoblasts are the parathyroid hormone (PTH) signaling 
and the sympathetic signaling, which will be further discussed in the next sections (FigureI. 3).  
iii. Endocrine functions of osteoblasts 
Aside from being the bone forming cells and regulating osteoclastogenesis through their secretion 
of Rankl and Opg, osteoblasts are also endocrine cells secreting at least, two hormones, FGF23 and 
osteocalcin. Among these, osteocalcin is a member of a larger family of proteins called GLA proteins. It 
contains 3 glutamic acid residues (GLA residues) that are γ-carboxylated by a specific vitamin K-
dependent γ-carboxylase.  
 Osteocalcin displays several features of a hormone. First, osteocalcin is initially synthesized 
as a pre-promolecule and secreted in the general circulation.  Later through post-translational 
modifications, the glutamic acid residues of osteocalcin undergoes carboxylation to form the γ -
carboxyglutamic acid (Gla) residues, a form of osteocalcin that has higher affinity for hydroxyapatite (HA) 
than the undercarboxylated osteocalcin (Hauschka et al. 1989). The last evidence that suggested that 
Osteocalcin is more than a bone- specific gene, hinting that skeleton may regulate energy metabolism via 
this gene was the observation of increased visceral fat, glucose intolerance and hypoinsulinemia that are 
displayed by Osteocalcin -/- mice (Lee et al. 2007). 
a. Regulation of energy metabolism by bone  
Further studies on the function of bone in regulation of energy metabolism demonstrated that the 
undercarboxylated form of osteocalcin is the biologically active form (Lee et al. 2007; Ferron et al. 2010). 
Osteocalcin regulates energy metabolism when undercarboxylated, specifically on the 13th carbon of the 
glutamic acid residue (GLU13) that is stimulated upon increase in bone resorption. The circulating levels 
of undercarboxylated osteocalcin favors proliferation, Insulin expression and insulin secretion in β-cells, 
as well as insulin sensitivity in the peripheral tissues (Ferron et al. 2010) (FigureI. 4-5). 
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b. Regulation of male fertility by bone 
One of the most powerful hormonal regulation of bone remodeling is via the sex steroid 
hormones, which is most commonly exemplified with the loss of gonadal function in post-menopausal 
women causing osteoporosis due to increased bone resorption (Pacifici 1998). Considering that gonads 
regulate bone remodeling, this brought up the question of whether bone could talk back to gonads to 
regulate them. 
First through cell culture experiments, it was shown that Leydig cells of the testes when cultured 
with the supernatant of osteoblasts, enhanced testosterone production, however this supernatant had no 
effect on the estrogen synthesis by the cultured ovaries. This experiment suggested that a secreted 
molecule must be responsible for affecting the androgen synthesis in the testes. Since, osteocalcin has 
been identified as an osteoblast-specific hormone regulating whole body glucose homeostasis and 
energy expenditure (Lee et al. 2007), and based on the hypothesis that energy metabolism, bone mass 
and reproduction are connected, along with the poor breeding observed in Osteocalcin-/- mice raised the 
hypothesis that osteocalcin might be signaling from bone to the testes. The mice deficient of Osteocalcin 
had a significant decrease in their testes size and weight, in addition to a decrease in their seminal 
vesicle and epididymes weights and sperm count, whereas in mice lacking Esp (Embryonic stem cell 
phosphatase), a negative regulator of osteocalcin bioactivity, these parameters were increased. It was 
further demonstrated that Osteocalcin exerts its action on the Leydig cells of testes through its receptor, 
OSTR or Gpcr6a, by activating a cAMP -dependent pathway to promote activation of the transcription 
factor, cAMP-binding response element (CREB) therefore up-regulating the genes necessary for 
testosterone biosynthesis (Oury et al. 2011). Specific deletion of Gpcr6a in Leydig cells of the testes, not 
only replicated the phenotype observed in mice lacking this gene globally but also it was a reflection of 
what was observed in Osteocalcin -/- mice (Pi et al. 2008; Oury et al. 2011).  
It was further established that insulin signaling in osteoblasts also favors male fertility by 
promoting the activation of osteocalcin through increased bone resorption (Ferron et al. 2010; Oury et al. 
2013a). Studies performed on patients with peripheral testicular insufficiency with unknown cause 
revealed that couple of these patients are heterozygous for a point mutation in the transmembrane region 
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of Gpcr6a resulting in a deleterious substitution, confirming the function of osteocalcin in male fertility in 
humans as well (Oury et al. 2013a) (FigureI. 5). 
c. Regulation of cognition and memory by bone 
Lastly, osteocalcin favors brain development and cognitive functions. The existence of strong 
regulation of bone mass exerted by brain raised the question of whether in turn, bone as an endocrine 
organ through osteocalcin regulates this or other functions of the brain (Takeda et al. 2002; Yadav et al. 
2009; Oury et al. 2010).  One striking observation about the mice that lack Osteocalcin set the bases for 
this work.  Over the years, investigators working with Osteocalcin-/- mice have realized their docile nature 
compared to WT mice.  When analyzed in dark/light cycles, it was also confirmed that these mice have 
decreased locomotion. Furthermore, it was observed that these mice are more anxious and depressed 
compared to WT mice, and have defects in memory and learning which extends to the maternal effect of 
osteocalcin. By subcutaneous infusion of mice with an osteocalcin pump demonstrated that osteocalcin 
crosses the blood-brain barrier. In addition, osteocalcin is also a hormone that crosses the placenta as 
demonstrated by the offspring of Osteocalcin-/- mice that display severe defects in spatial learning and 
memory. Maternal osteocalcin was shown to promote fetal neurogenesis in mice that do not have this 
hormone.  However, the action of osteocalcin in the brain is not through its only known receptor, OSTR, 
since mice lacking this receptor do not display any of the cognition or memory defects observed in 
Osteocalcin-/- mice. Therefore, the receptor through which osteocalcin exerts its action on brain still 
needs to be identified (FigureI. 5). 
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4. Systemic Regulation Of Bone Resorption 
The variety of the functions of osteoblasts leaves no doubt on the strict regulation of gene 
expression in these cells both intrinsically and via extracellular signals. This section will discuss in further 
detail the two extracellular cues that affect osteoblast function of bone resorption through different 
transcriptional means that are mediated by the same second messenger.  
i. Parathyroid hormone signaling 
Parathyroid hormone (PTH) is a major endocrine regulator of mineral homeostasis and bone 
mass. The initial appearance of PTH during evolution starts with the appearance of terrestrial animals and 
their movement from an aquatic environment to a Ca2+ deficient environment. The primary function of 
PTH is to control the Ca2+ homeostasis in the body considering that Ca2+ is an important mineral 
necessary for healthy neuromuscular function, bone mineralization and many other physiological 
processes (Marcus et al. 2001). PTH secretion is stimulated from the parathyroid glands upon decrease 
in the plasma Ca2+ levels. PTH acts directly on bone and kidney and indirectly on intestine to restore the 
Ca2+ levels in the blood (Brown 1991; Potts et al. 1997; Silverberg et al. 1999). Further studies 
established PTH as one of the major mediators of bone remodeling. Initially, the PTH action on bone was 
observed to promote bone resorption within 15 minutes of its administration (Holtrop and King 1977). 
Human PTH is 1-84 amino acid long peptide, which further gets processed into a shorter peptide 
of 1-34 amino acids, acting directly on kidneys and osteoblasts in bone, through PTH1 receptor, PTH1R 
(Silve et al. 1982; Teitelbaum et al. 1982; Goltzman et al. 1986). 1-34 amino acid sequence of PTH is 
known to bind and be sufficient for activating PTH1R (Mannstadt et al. 1999) (FigureI. 6).  
Several studies have shown that PTH1R is expressed only the osteoblastic cells in bone and that 
PTH alone was not able to promote differentiation of isolated osteoclasts in vitro unless osteoblasts-like 
cells were present in the environment (Goltzman et al. 1986; Jilka 1986). It was further established that 
direct contact between the osteoclasts and osteoblast-like cells were required for PTH-induced activation 
of osteoclasts. The explanation for these findings came from the discovery of RANKL and RANK receptor 
and their function in the regulation of osteoclastogenesis (Teitelbaum 2000). It is now established that 
PTH induces bone resorption indirectly by acting on osteoblasts to promote Rankl expression and 
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secretion, which then allows osteoclast differentiation and maturation, therefore increased bone 
resorption (O'Brien 2010). However, it is not clearly elucidated yet what are the molecular events initiated 
by PTH to enhance Rankl expression. 
PTH exerts its functions through PTH1R to mediate the regulation of PTH-dependent mineral 
homeostasis or paracrine actions of PTHrP during chondrogenesis (Abou-Samra et al. 1989; Mannstadt 
et al. 1999).  PTH1R is a G-protein coupled receptor with seven membrane-spanning helices, which 
further includes a large amino-terminal extracellular domain and an intracellular carboxyl-terminal domain 
similar to the family B (Class II) receptors that it belongs to. PTH1R can activate at least two second 
messenger dependent signal transduction pathways, cyclic–AMP (cAMP) dependent/protein kinase A 
(cAMP/PKA) or the phospholipase C/protein kinase C (PLC/PKC) pathways to mediate the functions of 
PTH and PTHrP to promote gene expression. cAMP is a second messenger involved in the action of 
various hormones and extracellular regulatory signals. PTH through its binding to PTH1R activates an 
enzyme called adenylyl cyclase (AC) to increase the cAMP levels in the cell. In turn, increasing levels of 
cAMP activates cAMP-dependent protein kinase A, PKA, which phosphorylates and therefore regulates 
proteins that are involved in physiological responses (FigureI. 7). PTH1R also activates PLC that is an 
enzyme responsible for producing diacylglycerol (DG) and soluble 1,4,5-inositol triphosphate (IP3), which 
also act as second messengers. DG and IP3 activate protein kinase C (PKC) and through their direct 
action on calcium channels increasing cytosolic-free calcium levels in the cell to transduce signals 
(FigureI. 7). 
Numerous studies have demonstrated that PTH1R is required for PTH stimulated bone resorption 
and that the action of PTH mediated by this receptor is through the activation of cAMP/PKA dependent 
pathway (Avioli and Krane 1990; Kondo et al. 2002). Cell-based assays also demonstrated that 
cAMP/PKA-dependent signaling of PTH requires cAMP-binding response element (CREB) action (Fu et 
al. 2002). However, in vivo deletion of Creb specifically in osteoblasts shows no abnormalities in Rankl 
expression or bone resorption suggesting that transcriptional means of PTH action is yet to be identified 
(Kajimura et al. 2011). 
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ii. Sympathetic signaling 
The sympathetic nervous system is another strong regulator of Rankl expression in osteoblasts 
(Elefteriou et al. 2005). Sympathetic signaling acts through its receptors β-adrenergic receptors (Adrβ). 
These receptors belong to a family of GPCRs that act by increasing intracellular cAMP levels and 
therefore activating PKA to promote phosphorylation of downstream targets controlling physiological 
events. β-adrenergic receptors are divided into sub-groups depending on their affinities to different 
agonists and antagonists: β1, β2 and β3 receptors (Takeda et al. 2002). 
The Adrenergic β2 receptor (Adrβ2) is the only adrenergic receptor expressed in osteoblasts. The 
importance of sympathetic signaling in regulation of bone remodeling was demonstrated through deletion 
of Adrβ2 receptor. Mice deficient of this receptor display a high bone mass phenotype (Takeda et al. 
2002). Besides an increase in bone formation parameters, Adrβ2-/- mice also display a significant 
decrease in their osteoclasts surface and deoxypyridinoline (Dpd) levels, a marker of osteoclast function. 
Further molecular analysis led to the understanding that sympathetic signaling promotes bone resorption 
through osteoblasts by inducing Rankl expression in a cAMP-dependent manner (Elefteriou et al. 2005). 
This action of sympathetic signaling in osteoblasts occurs through the transcription factor ATF4, which 
binds to the Rankl promoter inducing Rankl expression and thereby promoting bone resorption (Elefteriou 
et al. 2005). 
Aside from its function in regulating the bone resorption arm of bone remodeling, sympathetic 
signaling was also shown to indirectly regulate endocrine function of osteoblasts by affecting the 
bioactivity of Osteocalcin through Esp. The regulation of insulin secretion in β-cells of the pancreas in 
opposite ways via leptin and osteocalcin led to the discovery of the function of sympathetic signaling in 
the regulation of the energy metabolism (Hinoi et al. 2008). The hypoglycemic, hyperinsulinemic 
phenotype of Adrβ2osb-/- mice was due to the down- regulation of Esp expression. It was further 
demonstrated that sympathetic signaling promotes Esp expression also through the transcription factor 
ATF4 (Hinoi et al. 2008; Yoshizawa et al. 2009).   
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FigureI. 1. MEF2 proteins as central regulators of differentiation 
The tissues where the function of MEF2 proteins have been shown to promote many cellular processes 
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FigureI. 2. Osteoclastogenesis 
The studies on osteoporotic mouse models identified genes that play a major role in different stages of 
osteoclastogenesis. PU1 is essential for differentiation into the early macrophage precursors. Absence of 
M-csf results in the formation of immature macrophages.  Later during differentiation step, Rankl being 
the most important, c-fos and NFκΒ are necessary for normal macrophage differentiation into mature 
osteoclasts. c-src has also been shown to be important for polarization of the plasma membrane of 
osteoclasts and the absence of carbonic anhydrase II and H+-ATPase was shown to affect the resorbing 
ability of osteoclasts as the acidification of the resorptive environment is inhibited. Last but not least, 
cathepsin K is needed for degrading the organic matrix of bone Modified from (Teitelbaum 2000).  
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FigureI. 3. Mechanisms of Osteoclastogenesis  
 RANKL and M-CSF are synthesized by the osteoblast to promote the differentiation of macrophage 
progenitors into mature osteoclasts. RANKL binds to its receptor, RANK receptor, and M-CSF to c-fms. 
The expression of Rankl is upregulated by extracellular signals, e.g. PTH or catecholamines. The process 
of osteoclastogenesis is also negatively regulated by osteoblasts through the secretion of another 
molecule, OPG. Mature osteoclasts resorbs the bone through the use of Cl-/HCO3- channels to maintain 
an acidic pH of 4.5, as well as by their secretion of molecules e.g. Cathepsin K, a lysosomal protease. 
Modified from (Teitelbaum 2000).  
	  
	   24	  
 
 
FigureI. 4. Regulation of osteocalcin bioactivity via bone resorption 
RANKL promotes osteoclast differentiation and bone resorption whereas OPG inhibits this process. As 
the osteoclasts resorb bone, they form an acidic resorption lacuna of pH 4.5 that promotes 
decarboxylation and thereby, activation of osteocalcin. Circulating active osteocalcin promotes insulin 
secretion and sensitivity, as well as male fertility, and memory and cognition. Modified from (Karsenty and 
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FigureI. 5. Spectrum of the functions of bone-derived hormone osteocalcin 
Circulating active osteocalcin in the body promotes insulin sensitivity in insulin sensing tissues such as 
muscle, white adipose tissue (WAT), and liver; increases insulin secretion and β-cell proliferation in 
pancreas. Increases energy expenditure through brown adipose tissue (BAT); promotes testosterone 
production therefore favoring male fertility, and last but not least favors memory and cognition through its 
direct action on brain (Modified from (Karsenty 2011)). 
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FigureI. 6. The schematic representation of PTH 
1-34 amino acid of PTH has the ability to bind and promote cAMP production through PTH1R (Mannstadt 
et al. 1999) 
 
 
FigureI. 7. Model of PTH action on osteoblasts through PTH1R 
PTH binds to PTH1R, a GPCR, on osteoblasts to activate either Gs protein that promotes a cAMP-
mediated transcriptional control of osteoclastogenesis or Gq protein to activate a Ca2+/PKC pathway that 
has been shown to promote osteoblast proliferation (Karsenty 2011).  
  
	  












CHAPTER II. MANUSCRIPT 
	  
	   28	  
 Preface 
The completion of this work is owing to the contribution from many people. Dr. Arnaud Obri has been 
instrumental in the development of the project. He has confirmed several results I have obtained and 
performed most of the molecular work. Hdac5-/-, Mef2af/f and Mef2cf/f mice were originally generated 
and provided by Dr. Eric Olson. Ppr1f/f mice were generated and	  provided by Dr. Henry Kronenberg and 
Smurf2f/f mice are generated and provided by Dr. Hong Zhang.  Dr. Franck Oury helped me in performing 
the dissections for the testes parameters as well as in the establishment of Morris Water Maze test. Dr. 
Jianwen Wei and I performed the GSIS test on Hdac4osb-/- mice. Under the instruction Dr. Gerard 
















	   29	  
HDAC4 integrates PTH and sympathetic signaling to regulate multiple functions 
of osteoblasts 
	  
Arnaud Obri1,4, Munevver Parla Makinistoglu1,4, Hong Zhang2, Rhonda Bassel-Duby3, Eric Olson3 and 
Gerard Karsenty1* 
1 Department of Genetics and Development, Columbia University, New York, NY 10032, USA 
2 Department of Cell and Developmental Biology, University of Massachusetts Medical School, 
Worcester, MA 01655, USA 
3 Department of Molecular Biology, Southwestern University, Dallas, TX 75390, USA 
4 These authors contributed equally to this work 
Correspondence to: gk2172@columbia.edu. 
 
Abstract 
Both parathyroid hormone (PTH) and the sympathetic tone promote Rankl expression in osteoblasts and 
osteoclast differentiation by enhancing cAMP production, through an unidentified transcription factor for 
PTH and ATF4 for the sympathetic tone. How two extracellular cues using the same second messenger 
in the same cell elicit different transcriptional events is unknown. Here we show that PTH favors Rankl 
expression by triggering the ubiquitination of HDAC4, a class II histone deacetylase, partly via Smurf2. 
HDAC4 degradation releases MEF2c that transactivates the Rankl promoter. On the other hand, 
sympathetic signaling in osteoblasts favors the accumulation of HDAC4 and its association with ATF4. In 
this setting, HDAC4 increases Rankl expression. Through this interaction with ATF4, HDAC4 also 
influences Osteocalcin expression, and its endocrine and cognitive functions. This study shows that 
through its ability to differently connect distinct extracellular cues to their genome, HDAC4 is a global 
regulator of osteoblast functions.  
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Introduction   
Osteoblasts are bone-specific, multifunctional cells. Through their synthesis of proteins of the 
bone extracellular matrix, they are responsible for bone formation (Karsenty et al. 2009). Because 
osteoblasts express the osteoclast differentiation factor, RANKL, they also favor bone resorption 
(Simonet et al. 1997; Teitelbaum 2000). In addition, osteoblasts secrete two hormones, FGF23 and 
osteocalcin (Fukumoto and Martin 2009). The diversity of their functions explains why osteoblasts are 
influenced by multiple extracellular cues.  
One of them, the parathyroid hormone (PTH) regulates Rankl expression through several 
mechanisms (Tawfeek et al. 2010). In one capacity, PTH binds to its cognate receptor, PTH1R, a GPCR, 
on osteoblasts and enhances Rankl expression in a cAMP-dependent manner (Kondo et al. 2002). 
Consistent with this cAMP requirement, cell-based assays have suggested that CREB mediates the PTH 
regulation of Rankl expression (Fu et al. 2002). In vivo however, inactivation of Creb in osteoblasts does 
not affect Rankl expression or bone resorption (Kajimura et al. 2011) indicating that the transcriptional 
mechanisms whereby PTH signaling in osteoblasts affects Rankl expression may not be fully elucidated. 
Another systemic cue affecting Rankl expression in osteoblasts is the sympathetic nervous system. 
Catecholamines, following their binding to another GPCR, the β2 adrenergic receptor, also use cAMP as a 
second messenger to enhance Rankl expression by recruiting the transcription factor ATF4 (Elefteriou et 
al., 2005). The sympathetic tone also influences through ATF4, the expression and activity of the 
hormone osteocalcin (Hinoi et al. 2008). These observations raise the following question: How do two 
distinct regulatory signals that use the same second messenger elicit different transcriptional events and 
genetic programs in the same cell type?  
Chromatin structure, which is influenced by post-translational modifications of histone proteins 
around which the DNA is wrapped, is a major determinant of gene expression (Jenuwein and Allis 2001; 
Allis et al. 2006). Histone acetylation promotes gene transcription by relaxing the chromatin structure 
whereas deacetylation of histones by histone deacetylases (HDACs) induces chromatin condensation 
and transcriptional repression (Berger 2002; Verdin et al. 2003; Allis et al. 2006). A class of HDACs, the 
class II HDACs, besides containing a poorly active catalytic domain, has a long N-terminal extension to 
which transcription factors can bind. The existence of this domain has long suggested that class II 
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HDACs may serve as links between extracellular cues and the genome of a given cell (Verdin et al. 2003; 
Haberland et al. 2009). It is not known however, if and how a single class II HDAC molecule can integrate 
several extracellular cues to trigger different gene expression programs in the same cell.  
One class II HDAC, HDAC4, prevents chondrocyte hypertrophy in part by interacting with and 
inhibiting in proliferating chondrocytes the activity of the transcription factor Runx2, a master gene of 
skeletogenesis (Vega et al. 2004). Given the fundamental functions that Runx2 exerts during osteoblast 
differentiation and as a regulator of bone formation, this observation raises the question of whether 
HDAC4 also regulates Runx2 functions in osteoblasts (Karsenty et al., 2009).  In addressing the 
questions mentioned above, we show here that HDAC4 does not inhibit Runx2 functions in osteoblasts 
but rather integrates PTH and sympathetic signaling. HDAC4 inhibits Rankl expression in osteoblasts by 
interacting with MEF2c and preventing this transcription factor from transactivating the Rankl promoter. 
PTH signaling in osteoblasts favors Rankl expression by inducing, in part via the E3 ubiquitin ligase 
Smurf2, HDAC4 ubiquitination; this releases MEF2c that is now able to activate Rankl expression. In 
contrast, the sympathetic tone promotes HDAC4 accumulation in the nucleus of osteoblasts and its 
interaction with ATF4. Thus, under the control of the sympathetic tone, HDAC4 favors Rankl but also 
Osteocalcin expression and its endocrine and cognitive functions. We further show that HDAC4 does not 
inhibit Runx2 functions in osteoblasts because catecholamines disrupt the physical interaction between 
HDAC4 and Runx2. This study unravels the transcriptional bases of PTH regulation of Rankl expression 
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Results 
HDAC4 inhibits Rankl expression in osteoblasts  
With the goal of deciphering the functions of class II histone deacetylases (HDACs) in 
osteoblasts, we asked which ones were more highly expressed in these cells. Hdac5 was, by far, the 
most highly expressed class II Hdac in osteoblasts (Figure 1A), its expression in bone being at least two-
fold higher than in any other tissues tested (Figure 1B). Hdac4 was the second highest expressed 
member of this gene family in osteoblasts; its expression was also higher in bone than in several other 
tissues like cartilage, brain and heart where this gene exerts important functions (Figure 1A-B) (Zhang et 
al. 2002; Chang et al. 2004; Vega et al. 2004). Similar results were obtained at the protein level (Figure 
1C). 
Given this pattern of expression, we focused our studies on HDAC4 and HDAC5 to elucidate the 
roles of class II HDACs in osteoblasts. For that purpose, we used Hdac5-/- mice and generated mice 
lacking Hdac4 in cells of the osteoblast lineage to overcome the perinatal lethality of Hdac4-/- mice (Vega 
et al. 2004), This was achieved by crossing Hdac4fl/fl mice with mice expressing the Cre recombinase 
under the control of Runx2 regulatory elements (Rauch et al. 2010). Prior to using Hdac4osb-/- mice we 
verified that Hdac4 had been efficiently deleted from osteoblasts but not from other cell types and that 
there was no overexpression of either Hdac4 in the Hdac5-/- mice or of Hdac5 in the Hdac4osb-/- mice 
(Figure S1A, B).  Since HDAC4 inhibits Runx2 functions in chondrocytes, we expected that it would do 
the same in osteoblasts and that Hdac4osb-/- mice would display high bone mass because of increased 
osteoblast numbers and bone formation. 
Instead, both Hdac4osb-/- and Hdac5-/- mice demonstrated a low bone mass phenotype of similar 
intensity and affecting all bones analyzed (Figure 1D-E). This was caused by a 50% increase in the bone 
surface covered by osteoclasts compared to control mice whereas osteoblast numbers and bone 
formation rates were unaffected (Figure 1D). Accordingly, circulating levels of CTX, a byproduct of 
collagen degradation and a biomarker of bone resorption (Rosen et al. 2000), were significantly higher in 
Hdac4osb-/- and Hdac5-/- than in control mice (Figure 1F). This increase in bone resorption was caused by 
a 2- to 10-fold increase in Rankl expression in Hdac4-/- and Hdac5-/- compared to control osteoblasts 
while Opg expression was not changed to the same extent (Figure 1G-H). As a result, the ratio of 
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Rankl/Opg was increased over 50% in Hdac4-/- and Hdac5-/- compared to WT osteoblasts (Figure 1I). 
Expression of other regulatory genes, such as Runx2, Atf4, FoxO1, Mef2a and Mef2c and of type I 
collagen was normal in Hdac4-/- or Hdac5-/- bones (Figure S1C). These results indicate that through their 
expression in osteoblasts, HDAC4 and HDAC5 inhibit Rankl expression and bone resorption but do not 
affect bone formation. An explanation for the absence of influence of HDAC4 or HDAC5 on bone 
formation is proposed below (see Figure 4H). For the rest of this study, because of the cell-specific nature 
of the gene deletion, we privileged the analysis of Hdac4osb-/- mice.  
 
HDAC4 inhibits osteoclast differentiation by preventing MEF2c to transactivate Rankl  
As a way to elucidate how HDAC4 inhibits Rankl expression in osteoblasts, we asked whether 
members of the MEF2 family of transcription factors regulate Rankl expression. This question was 
prompted by the documented interaction of HDAC4 with members of this family of transcription factors in 
other cell types (Zhang et al. 2002; Kozhemyakina et al. 2009), and by the presence in the mouse Rankl 
promoter of 3 putative MEF2 binding sites that are conserved in all vertebrate species analyzed (Figure 
2A). 
Among the members of the Mef2 gene family Mef2a and Mef2c were by far the most highly 
expressed in osteoblasts (Figure 2B). Chromatin immunoprecipitation assays verified that MEF2 protein 
could bind to each of the putative MEF2 binding sites present in the mouse Rankl promoter (Figure 2C), 
and in DNA co-transfection assays performed in COS cells that do not express Rankl, an expression 
vector for Mef2c transactivated a construct containing a 3kb-long fragment of the Rankl promoter driving 
the luciferase gene (pRankL-luc) (Figure 2D). Disrupting each of these three binding sites decreased the 
activity of this promoter fragment by 50% or more and abrogated MEF2c ability to activate this RankL-luc 
construct (Figure 2D) thus illustrating the importance of MEF2 proteins for Rankl expression in 
osteoblasts.  
To assess the respective importance of MEF2a and MEF2c in the regulation of Rankl in vivo, we 
generated mutant mice lacking either Mef2a or Mef2c in an osteoblast-specific manner (Mef2aosb-/- and 
Mef2cosb-/-). We verified that this manipulation had efficiently deleted Mef2c or Mef2a from osteoblasts 
but not from other cell types (Figure S2). Since our goal is to understand how HDAC4 regulates Rankl 
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expression, we focused our analysis on Rankl expression and bone resorption. While mice lacking Mef2a 
in osteoblasts did not display any abnormalities of bone resorption, Mef2cosb-/- mice exhibited a significant 
decrease in the bone surface covered by osteoclasts in all bones analyzed (Figure 2E). Serum CTX 
levels were also significantly lower in Mef2cosb-/- than in Mef2cfl/fl mice and Rankl expression was 
decreased nearly 50% in Mef2cosb-/- compared to control osteoblasts (Figure 2F-G). These results 
indicate that through its expression in osteoblasts, MEF2c is essential for Rankl expression in osteoblasts 
and osteoclast differentiation.  
The opposite influence of HDAC4 and MEF2c on Rankl expression along with the ability of 
HDAC4 to interact physically with MEF2c prompted us to test whether HDAC4 inhibits Rankl expression 
by hampering the transactivating function of MEF2c. In DNA co-transfection experiments, the ability of 
MEF2c to transactivate the RankL-luc construct in COS cells was abrogated when either a Hdac4 or a 
Hdac5 expression vector was co-transfected (Figure 2H). More importantly in vivo, Rankl expression, 
serum CTx values as an indicator of bone resorption and bone mass were normal in Hdac4osb-/- mice 
lacking one allele of Mef2c in osteoblasts only (Hdac4osb-/-; Mef2cosb+/-) (Figure 2I-L). Taken together the 
experiments presented above reveal the existence of an HDAC4 ┨MEF2c  Rankl regulatory loop 
taking place in osteoblasts in the mouse. 
 
PTH favors Rankl expression through MEF2c by promoting HDAC4 proteasomal degradation 
Given that the transcriptional means whereby PTH signaling in osteoblasts promotes Rankl 
expression are not completely understood, we asked whether PTH favors Rankl expression in 
osteoblasts, in part, by disrupting the HDAC4 ┨ MEF2c  Rankl pathway. 
Consistent with this hypothesis we observed that PTH (10nM) consistently increased the activity 
of the 3kb-long Rankl promoter fragment in ROS17/2.8 osteoblastic cells and that mutating the first MEF2 
binding site in this promoter was sufficient to abrogate this effect of PTH (Figure 3A). Remarkably we also 
observed, whether this analysis was done by western blot or by immunofluorescence, that PTH triggers a 
marked decrease in HDAC4 accumulation in both the cytoplasm and the nucleus of mouse osteoblasts, 
while it did not decrease MEF2c accumulation in the nucleus of these cells (Figure 3B-D).  
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This was different from what is observed following treatment of chick chondrocytes with PTHrP, a 
molecule that bears similarities with PTH and that signals through the same receptor (Kronenberg 2003). 
Indeed, PTHrP allows HDAC4 to move to the nucleus by inducing its dephosphorylation on S246 
(Kozhemyakina et al. 2009). PTH did induce this dephosphorylation event in HDAC4 in mouse 
osteoblasts (Figure 3E) but this could not explain our findings since PTH induces a near complete 
disappearance of HDAC4 from osteoblast nuclei (Figure 3C). Since PTH does not decrease Hdac4 
expression in osteoblasts (Figure S3A), we asked if instead PTH induces proteasomal degradation of 
HDAC4 in osteoblasts.  In support of this idea, the PTH-induced decrease of HDAC4 accumulation in 
osteoblasts was prevented by the addition of an inhibitor of proteasomal degradation, bortezomib (Figure 
3B-C). Bortezomib also significantly decreased the ability of PTH to up-regulate Rankl expression in 
osteoblasts (Figure 3F). Moreover, treating osteoblasts with PTH and bortezomib induced 
polyubiquitination of HDAC4 (Figure 3G). In view of these results, we asked whether PTH regulates the 
expression of any E3 ubiquitin ligases that are expressed in osteoblasts. 
 Among the E3 ubiquitin ligases that are highly expressed in osteoblasts (Severe et al. 2013), the 
expression of 2 of them, Smurf2  and Synv1 was significantly increased by PTH (Figure 3H). The 
regulation of Smurf2 expression by PTH was specific since another extracellular signal, isoproterenol 
used as a surrogate of the sympathetic tone, did not affect Smurf2 expression (Figure S3B). In view of 
these results, we studied the possible role of Smurf2 and Synv1 downstream of PTH signaling in 
osteoblasts through siRNA knockdown experiments. In each experiment we verified that we had 
efficiently decreased either Smurf2 or Synv1 accumulation, while not affecting Hdac4 expression (Figure 
S3C). Decreasing Synv1 accumulation in osteoblasts increased Rankl expression and did not prevent 
PTH from inducing Rankl expression (Figure 3I). In contrast, decreasing Smurf2 accumulation in mouse 
osteoblasts significantly lowered the expression of Rankl and hampered the ability of PTH to induce 
Rankl expression (Figure 3I-J). Moreover, Smurf2 interacts with HDAC4 only if osteoblasts were treated 
with PTH (Figure 3K). In further support of a role of Smurf2 in the PTH regulation of Rankl expression, we 
observed that the PTH induction of Rankl expression was decreased nearly 50% in osteoblasts lacking 
one allele of Ppr encoding the PTH receptor and one allele of Smurf2 (Figure 3L). Thus, our results 
suggest that one mechanism whereby PTH favors Rankl expression in osteoblasts is by recruiting Smurf2 
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to ubiquitinate HDAC4. This abrogates the well known physical interaction taking place between HDAC4 
and MEF2c and allows MEF2c to activate the Rankl promoter (Backs et al. 2008).  
 
The sympathetic tone favors Rankl expression by stabilizing HDAC4 
The observation that PTH regulates Rankl expression in an HDAC4-dependent manner raised 
the hypothesis that another systemic regulator of Rankl expression in osteoblasts, the sympathetic 
nervous system (Elefteriou et al. 2005), might also recruit HDAC4 to achieve this function.  
To test if it was the case, we treated mouse osteoblasts with isoproterenol (ISO) (10µM), a 
surrogate of the sympathetic tone. Like PTH, ISO favored Hdac4 and to a lesser extent Hdac5 expression 
(Figure 4A). However unlike PTH, ISO increased HDAC4 accumulation in the nucleus of osteoblasts and 
promoted the interaction of this class II HDAC with ATF4 (Figure 4B-C). ISO also decreased the 
phosphorylation of HDAC4 on S246 an event that favors translocation of HDAC4 to the nucleus (Figure 
4D). Accordingly, mice lacking one allele of Hdac4 and one allele of Atf4 only in osteoblasts (Atf4osb+/-; 
Hdac4osb+/- mice) demonstrated a significant decrease in Rankl expression, circulating CTx values and 
the bone surface covered by osteoclasts (Figure 4E-G). Thus, both PTH and the sympathetic tone target 
HDAC4 to promote Rankl expression but they do so differently. PTH favors HDAC4 degradation to allow 
MEF2c to increase Rankl expression; the sympathetic tone instead enhances HDAC4 accumulation to 
favor its interaction with ATF4 and Rankl expression.  
Of note, while it increased the interaction between HDAC4 and ATF4, ISO treatment of 
ROS17/2.8 osteoblastic cells disrupted the interaction between HDAC4 or 5 and Runx2. Similar results 
were obtained when using mouse primary osteoblasts (Figure 4H). This latter observation is important as 
it provides an explanation for why in the living animal in which the sympathetic signaling is constantly 
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HDAC4 regulates osteocalcin endocrine and cognitive functions through its expression in 
osteoblasts. 
Osteoblasts are also endocrine cells. Since ATF4 regulates the expression of one of the 
osteoblast-derived hormones, Osteocalcin (Yang et al. 2004), the interaction between ATF4 and HDAC4 
presented above raised the prospect that HDAC4 might also affect the endocrine and cognitive functions 
mediated by osteocalcin.  
Expression of Osteocalcin as well as of Esp, a gene encoding an inhibitor of osteocalcin activity 
(Lee et al. 2007), was decreased in Hdac4osb-/- and in Atf4osb+/-; Hdac4osb+/- but not in Hdac5-/- bones 
thus revealing one functional difference between these two class II HDACs (Figure 5A). This feature of 
Hdac4osb-/- mice was expected since ATF4, with whom HDAC4 interacts, regulates the expression of both 
genes (Yang et al. 2004; Yoshizawa et al. 2009). Circulating levels of total and undercarboxylated i.e., 
active, osteocalcin were decreased in Hdac4osb-/- and Atf4osb+/-;Hdac4osb+/- mice (Figure 5B). This 
decrease, however, was less severe than one would have anticipated given the marked decrease in 
Osteocalcin expression in Hdac4osb-/- bones (Figure 5A). There may be two complementary explanations 
for this. First, the decreased expression of Esp, a negative regulator of osteocalcin bioactivity (Lee et al. 
2007), should oppose the decrease in the circulating levels of active osteocalcin; second, the increase in 
bone resorption, a positive regulator of osteocalcin undercarboxylation (Ferron et al. 2010), seen in 
Hdac4osb-/- mice should also counteract the effect of the decrease in Osteocalcin expression on the 
circulating levels of active osteocalcin in Hdac4osb-/- mice. Nevertheless, osteocalcin circulating levels 
were significantly decreased in Hdac4osb-/- mice, an observation that prompted us to analyze their 
endocrine and cognitive functions.  
Circulating levels of insulin were decreased in both Hdac4osb-/- and in Atf4osb+/-;Hdac4osb+/- mice 
(Figure 5C-D), moreover, Hdac4osb-/- mice displayed a decrease in insulin secretion as measured by a 
glucose-stimulated insulin secretion (GSIS) test (Figure 5E), and a significant decrease in the β-cell area 
and in insulin content in their pancreata (Figure 5F-G). That insulin sensitivity was not affected in 
Hdac4osb-/- mice (Figure S4) is consistent with the relatively mild decrease in the circulating levels of 
undercarboxylated osteocalcin since we know that this function of osteocalcin requires a higher threshold 
of signaling to be affected (Ferron et al. 2008). Osteocalcin also favors male fertility by signaling in cells of 
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the testes (Oury et al. 2011). Accordingly testes size and weight, epididymes and seminal vesicle 
weights, sperm count and testosterone levels were all decreased in Hdac4osb-/- mice (Figure 5H-J). 
Lastly, osteocalcin favors spatial learning and memory, and these two functions are hampered in 
Osteocalcin+/- mice (Oury et al. 2013). In a Morris Water Maze test (MWMT) assessing spatial learning 
and memory through the ability of mice to find a submerged platform using spatial cues (Morris et al. 
1982), Hdac4osb-/- mice performed as poorly as Osteocalcin+/- mice (Oury et al. 2013b) (Figure 5K). 




This study, initiated to better understand the functions of class II HDACs in osteoblasts, revealed 
several novel molecular aspects of osteoblast biology. It identified a transcriptional mediator of PTH 
signaling in osteoblasts and showed that HDAC4 and HDAC5 integrate, in different ways, two 
extracellular cues, PTH and the sympathetic tone. This triggers different transcriptional events in 
osteoblasts that result in the enhancement of Rankl expression and of the endocrine and cognitive 
functions of osteoblasts. Lastly, it provides an explanation for why HDAC4 does not inhibit Runx2 function 
in osteoblasts as it does in chondrocytes. 
 
Class II HDACs expression and functions in osteoblasts  
The role of HDAC4 as an inhibitor of Runx2 functions in proliferating chondrocytes (Vega et al. 
2004), begged the question of the role that this or any other class II HDACs might have in osteoblasts, a 
cell type where Runx2 is so important before and after birth (Ducy et al. 1997; Komori et al. 1997; Otto et 
al. 1997; Ducy et al. 1999). Two class II HDACs, HDAC4 and HDAC5, are highly expressed in 
osteoblasts. To our surprise however, deletion of either one of these 2 class II HDACs in osteoblasts 
does not result in the expected increase in Runx2 function and therefore in an increase in bone formation 
and bone mass. Instead both Hdac5-/- and Hdac4osb-/- mice display a low bone mass because of an 
isolated increase in bone resorption parameters. Further molecular and genetic tests showed that through 
their expression in osteoblasts Hdac4 and Hdac5 prevent expression of Rankl, the major osteoclast 
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differentiation factor (Teitelbaum, 2000). They do so because through their interaction with MEF2c, they 
prevent this transcription factor to activate the Rankl promoter (Figure 6). These results show that class II 
HDACs have different modes of action in two related skeletal cell types, chondrocytes and osteoblasts. 
Since Runx2 is expressed in osteocytes (Ducy et al. 1999), the Cre-expressing mouse used in this study 
should delete genes equally well in osteoblasts and osteocytes (Rauch et al. 2010). Therefore, we 
anticipate that the mechanism of action described in this study may be at work in osteocytes where Rankl 
expression is so high (Nakashima et al. 2011; Xiong et al. 2011). Further experiments using an osteocyte-
specific Cre deleting mouse will address this question. 
 
PTH regulation of Rankl expression 
The notion that class II HDACs serve as links between extracellular cues and the genome of a 
given cell, together with the uncertainties regarding the transcriptional mode of action of PTH in 
osteoblasts led us to ask whether PTH signaling in osteoblasts interferes with the regulatory loop 
mentioned above to favor Rankl expression.  
Several lines of evidence indicate that it is the case and that PTH does so through a different 
mechanism than the one used by its close relative, PTHrP, in chick chondrocytes (Kozhemyakina et al. 
2009). Indeed, PTH treatment of osteoblasts causes a near disappearance of HDAC4 away from any 
compartment in osteoblasts, a phenomenon blocked by inhibiting proteasomal degradation, whereas 
PTHrP treatment of chick chondrocytes causes an accumulation of HDAC4 in the nucleus 
(Kozhemyakina et al. 2009). Accordingly for these differences PTH enhances expression in osteoblasts of 
at least one E3 ubiquitin ligase, Smurf2, and is necessary for the interaction of Smurf2 and HDAC4 to 
occur. Accordingly, PTH triggers a Smurf2-dependent degradation of HDAC4 and the PTH ability to 
induce Rankl expression is diminished by decreasing Smurf2 accumulation in osteoblasts and in Ppr+/-
;Smurf2+/- osteoblasts. Further genetic evidence is now needed to determine the in vivo importance of 
Smurf2 in the ubiquitination of HDAC4 in osteoblasts. Our results do not rule out that other E3 ubiquitin 
ligases, not identified in this study, contribute to the PTH-mediated ubiquitination of HDAC4. Finally we 
should also emphasize that our results do not contradict and do not exclude in any way the fact that PTH 
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also favors Rankl expression in osteoblasts by signaling in T-lymphocytes as it has been demonstrated 
(Gao et al. 2008; Tawfeek et al. 2010). 
 
Sympathetic signaling in osteoblasts and class II HDACs 
PTH is not the only extracellular cue recruiting HDAC4 in osteoblasts to mediate its functions. Our 
results show that the sympathetic tone does the same although it exerts a totally different influence than 
PTH on HDAC4 accumulation.  
Like PTH, the sympathetic tone favors Hdac4 and Hdac5 expression but unlike PTH, the 
sympathetic tone favors the accumulation of HDAC4 in osteoblasts and its interaction with ATF4, the only 
known transcriptional mediator of the sympathetic regulation of Rankl expression (Elefteriou et al. 2005). 
The biological importance of the HDAC4-ATF4 interaction was demonstrated in vivo by showing that 
Atf4osb+/-;Hdac4osb+/- mice demonstrate a decrease in Rankl expression and in bone surface covered by 
osteoclasts.  This mechanism is different from the PKA-induced proteolysis described by Backs et al., in 
cardiomyocytes (Backs et al. 2011). Although we cannot exclude that such a proteolysis occurs in 
osteoblasts, we note that if it were the case it would prevent expression of Rankl whereas ISO increases 
it.  The different mechanisms whereby PTH and the sympathetic tone use HDAC4 as an intermediary 
step to fulfill their functions in osteoblasts (Figure 6) suggest that these two extracellular cues recruit 
different signaling molecules. Further biochemical studies will help clarify this aspect of PTH and 
sympathetic signaling in osteoblasts.  
 
Sympathetic signaling, class II HDACs and Runx2 function in osteoblasts 
HDAC4 importance during skeletogenesis first came to light when it was shown that it interacts 
physically with Runx2 to inhibit the transactivating function of this factor in proliferating chondrocytes, and 
therefore chondrocyte hypertrophy (Vega et al. 2004). Given these results, it came as a surprise that 
neither HDAC4 nor HDAC5 deletion in osteoblasts affected osteoblast numbers and bone formation, two 
classical functions of Runx2 (Ducy et al. 1997; Komori et al. 1997; Karsenty et al. 1999). Our experiments 
indicate that while it favors ATF4 interaction with HDAC4 and HDAC5, catecholamines inhibit the physical 
interaction between HDAC4 or HDAC5 and Runx2 in osteoblasts. Since catecholamines are constantly 
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present in bones, which are vascularized and highly innervated tissues (Chenu 2004; Lafage-Proust et al. 
2010), this observation provides a plausible explanation for the fact that HDAC4 and HDAC5 deletions in 
osteoblasts do not affect osteoblasts number and bone function. Since cartilage is avascular and poorly 
innervated if at all the interaction between HDAC4 and Runx2 can occur in chondrocytes (Vega et al., 
2004). This finding also underscores the physiological importance of sympathetic signaling in osteoblasts 
in determining bone mass accrual (Takeda et al. 2002; Elefteriou et al. 2005).  
 
Hdac4 expression in osteoblasts and endocrine and cognitive functions of the osteoblasts 
The central role that HDAC4 and HDAC5 play as partners of ATF4 begged the question of their 
involvement in regulating the functions of osteocalcin, a hormone made by osteoblasts and whose 
expression is regulated by ATF4 (Ducy and Karsenty 1995; Yang et al. 2004). This is an important 
question to address if one wants to achieve a better molecular understanding of the emerging role of the 
osteoblasts as a multipurpose cell type (Karsenty and Ferron 2012). Our studies show that, in cell culture 
like in vivo, HDAC4 but not HDAC5 regulates osteocalcin expression, accumulation and bioactivity. As a 
result and through its expression in osteoblasts, HDAC4 favors insulin secretion, glucose homeostasis, 
male fertility and spatial learning and memory. The fact that HDAC5 does not fulfill the same function than 
HDAC4 in this setting suggests that each class II HDAC might interact with different factors. In a broader 
sense, the results presented here underscore the importance of HDAC4 compared to other class II 
HDACs as a global regulator of several functions of the osteoblast (Figure 6), and are an incentive to look 




For all the in vivo analysis except for the Morris Water Maze test male mice of indicated ages 
were used. In the Morris Water Maze test, female mice of 3-month of age were used. Generation of 
Hdac5-/- mice was previously reported (Chang et al. 2004). Hdac4osb-/- mice were generated by 
intercrossing Hdac4fl/fl mice with Runx2-Cre transgenic mice (Rauch et al. 2010).  Mef2aosb-/- and 
Mef2cosb-/- mice (C57BL/6J) were generated by intercrossing Mef2afl/fl or Mef2cfl/fl mice (Lin et al. 1997; 
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Akhtar et al. 2012) and Runx2-Cre transgenic mice. Hdac4osb-/-;Mef2cosb+/- mice were obtained from 
crosses between F2 generation Hdac4osb +/-;Mef2cosb+/- and Hdac4fl/fl or Hdac4osb+/- and Hdac4osb+/-
;Mef2cosb+/- mice.  Hdac4osb+/-;Atf4osb+/- mice were generated by crossing Atf4fl/fl or Atf4fl/+ mice with 
Hdac4osb+/- mice. Mice genotypes were determined by PCR (primer sequences available upon request).  
Floxed mice and Cre expressing mice were used as controls. All animal procedures were approved by 
CUMC IACUC and conform to the relevant regulatory standards. 
 
Bone histomorphometry  
Lumbar vertebrae or tibia dissected from 2- or 3- month old mice were fixed for 24 hours, 
dehydrated with graded concentrations of ethanol and embedded in methyl methacrylate (MMA) resin 
according to standard protocols. Von Kossa/Van Gieson, toluidine blue and tartrate-resistant acid 
phosphatase (TRAP) stainings were used to measure bone volume over tissue volume (BV/TV), 
osteoblast and osteoclast numbers and surface, respectively. Bone formation rates were assessed 
following calcein double-labeling. Calcein (Sigma Chemical Co., St. Louis, MO) was dissolved in calcein 
buffer (0.15 M NaCl, 2% NaHCO3) and injected twice at 0.125 mg/g body weight on days 1 and 4, and 
mice were killed on day 6. All quantifications were performed using Osteomeasure Analysis system 
(Osteometrics, Atlanta GA). 
 
Metabolic Studies and Bioassays 
For insulin tolerance test (ITT), mice were fasted for 4 hours, and then insulin (0.44U/kg) was 
given with intraperitoneal injection (IP). Blood glucose levels were measured at indicated time points 
using the Accu-Chek active system (Roche).  For glucose-stimulated insulin secretion (GSIS) test, mice 
were fasted for 16 h an injected IP with 3g/kg of glucose. Blood was collected from the tail of the mice at 
indicated time points and serum insulin levels were assessed using the Ultra-sensitive Insulin ELISA kit 
(Crystal Chem). Random insulin levels in mice were measured in tail blood collected and assayed with 
the mouse/human insulin ELISA (Mercodia). Pancreas insulin content and histology was performed as 
previously described (Lee et al. 2007; Ferron et al. 2010). CTX were measured using the RatLaps ELISA 
(ImmunoDiagnostics). Total and undercarboxylated osteocalcin levels were obtained using a previously 
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described ELISA (Ferron et al. 2010) Serum testosterone levels were measured by radioactive 
immunoassay (Alpco).  
 
Cell-based assays 
Mouse osteoblasts were prepared as previously described (Ducy and Karsenty 1995; Ferron et 
al. 2010). For in vitro gene inactivation, floxed osteoblasts were divided into two groups and infected with 
either GFP- or Cre-expressing adenovirus (University of Iowa). For siRNA transfections, osteoblasts were 
transfected with siRNA pools (On-TARGETplus, Dharmacon) according to the manufacturer instructions. 
For immunofluorescence cells were trypsinized, re-plated after two days of culture and left in regular 
media conditions for one day. On experiment day, cells were washed twice with PBS and treated with 
indicated amount of PTH (1-34) (PROSPEC), ISO (Sigma) and bortezomib (Selleckchem) for 2 hours. 
Immunofluorescence was performed using a standard protocol. For gene expression, osteoblasts were 
cultured in α-MEM containing 10% FBS supplemented with 5 mM β-glycerophosphate and 100 µg/ml 
ascorbic acid for 10 days. Cells were fasted in serum-free media for 16 hours and treated with indicated 
amount of PTH or ISO or bortezomib for 2 hours. Cells were then collected in TRizol (Invitrogen), RNA 
isolation, cDNA preparation, and qPCR analyses were carried out following standard protocols. 
 
Molecular biology and Biochemistry 
For DNA co-transfection assays COS cells were cultured in DMEM supplemented with 10% FBS. 
Cells were transfected with pCMV14-FLAG-MEF2c (100ng), pCDNA3.1-HA-HDAC4 (10ng) or pCDNA3.1-
HA-HDAC5 (10ng) expression vectors, pRankl-luc, pRankls1-luc, pRankls2-luc or pRankls3-luc (5ng) and 
pCMV-β-gal reporter vectors. DNA transfections were performed in ROS17/2.8 cells cultured in DMEM 
F12 (1:1) supplemented with 10% FBS. Cells were transfected with pRankl-luc (5ng) or pRankls1-luc 
(5ng) and pCMV-β-gal (200ng) reporter vectors. Thirty-two hours after transfection cells were washed 
with PBS and treated with serum-free media containing either 10nM PTH or vehicle for indicated times. 
Luciferase and β-gal assays were performed using standard procedures. For co-immunoprecipitation 
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assays, ROS17/2.8 cells were transfected with pCMV5-FLAG-ATF4 (6 µg), pCMV5-FLAG-Runx2 (6 µg), 
pCMV5-Smurf2 (6ug) with either pCDNA3.1-HA-HDAC4 (2 µg) or pCDNA3.1-HA-HDAC5 (2 µg). Forty-
eight hours later cells were washed with PBS and treated with media containing 0.1% FBS and indicated 
amount of PTH or Bortezomib or ISO for 2 hours. Cells were lysed in hypotonic buffer and disrupted by 
Dounce homogenizer. The cytosolic fraction was separated from the pellet by centrifugation at 4°C. The 
nuclear-soluble fraction was obtained by incubation of the pellet in high-salt buffer to get a final NaCl 
concentration of 300mM. Tagged proteins from each fraction were immunoprecipitated with anti-Flag M2 
overnight. The next day protein G-agarose beads were added and incubated for 2 hours at 4°C. Each IP 
was washed 5 times with TGEN 150 buffer (20mM Tris at pH 7.65, 150mM NaCl, 3mM MgCl2, 0.1mM 
EDTA, 10% glycerol, 0 0.01% NP40), proteins were eluted with Laemmli buffer and boiled for 10 minutes. 
Antibodies used in this study are anti-FLAG (Sigma), anti-MEF2c (Abcam,), anti-MEF2 (Santa 
Cruz Biotechnology), anti-HDAC4 (Santa Cruz Biotechnology), anti-HA (Cell Signaling Technology), anti-
HDAC5 (Cell Signaling Technology), anti-phospho-HDAC4 S-246 (Cohen et al. 2007), anti-GAPDH (Cell 
Signaling Technology), and anti-ubiquitin (Cell Signaling Technology). DAPI was included in the mounting 
media (EMS).  
 
Chromatin immunoprecipitation 
Mouse osteoblasts were washed twice with PBS and cross-linked with 1.1% formaldehyde for 10 
minutes at 37°C. Crosslinking was stopped by 125mM glycine with gentle rocking. Cells were washed with 
PBS containing 0.25mM PMSF, nuclear extracts prepared and each sample sonicated to obtain sheared 
fragments of 200-800 bp. Samples were pre-cleared with normal rabbit IgG with incubation for 1 hour and 
agarose G beads for 2 hours at 4°C. An anti-MEF2 antibody was added to cleared lysates and incubated 
overnight at 4°C. The next day, agarose protein G beads were blocked with 200 µg/ml salmon sperm 
DNA and 1mg/ml BSA for 1 hour at 4°C. Lysates were incubated with blocked beads for 2 hours at 4°C, 
washed in low salt buffer, twice in high salt, twice in LiCl buffer and twice in TE buffer. Washed beads 
were eluted in elution buffer by incubating at 37°C for 2 hours. The DNA was reverse cross-linked by 
incubating all samples at 65°C for 6 hours. Following DNA extraction, PCR analysis was performed on 
ChIPed material with oligonucleotides designed to detect the Mef2 binding sites within the mouse Rankl 
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promoter.   
 
Morris Water Maze test 
The test was performed on female mice only and as previously described (Oury et al., 2013). 
Statistical analysis 
Results are given as means ± standard error of the mean (SEM). Statistical analyses were performed 
using unpaired, two-tailed Student's t-test. In all figures error bars represent SEM and * represents 
p<0.05.  
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Figure 1. HDAC4 and HDAC5 inhibit Rankl expression in osteoblasts 
(A) Analysis of Class IIa Hdacs expression in WT osteoblasts (n=3). The expression of each gene is 
compared to the one of Hdac5. (B) Analysis of Hdac4 (right panel) and Hdac5 (left panel) expression in 
various tissues (n=3). Expression of these 2 genes in each tissue is compared to their expression in 
muscle. (C) Western blot analysis of HDAC4 and HDAC5 accumulation in different tissues. Anti-GAPDH 
was used as a loading control. (D) Histomorphometric analyses of vertebrae of 3 month-old Hdac4osb-/- 
(n=7) and Hdac5-/-  (n=7) mice compared to Hdac4fl/fl  (n=8) or WT (n=5) controls respectively. BV/TV%: 
percentage of bone volume over trabecular volume; Nb.Ob/T.Ar.: number of osteoblasts per trabecular 
area; BFR: bone formation rate; OcS/BS%: percentage of osteoclast surface per bone surface. (E) 
Histomorphometric analyses of long bones of 3 month-old Hdac4fl/fl (n=6), Hdac4osb-/- (n=5), WT (n=5) 
and Hdac5-/- (n=6). (F) Serum CTX levels in 3 months-old Hdac4fl/fl (n=13), Hdac4 osb-/- (n=12), WT 
(n=10), Hdac5-/- (n=9). Results are expressed as fold changes compared to levels seen in Hdac4fl/fl 
mice. (G) Analysis of Rankl expression in Hdac4fl/fl (n=4), Hdac4-/- (n=4) (left panel), WT(n=4) and 
Hdac5-/- (n=4) (right panel) osteoblasts. Results are presented as fold changes compared to levels seen 
in Hdac4fl/fl or WT osteoblasts. (H, I) Analysis of Opg expression (H) and Rankl/Opg ratio (I) in Hdac4fl/fl 
(n=4), Hdac4-/- (n=4), WT (n=4) and Hdac5-/- (n=4) osteoblasts. Results are expressed as fold changes 
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Figure 2. HDAC4 prevents MEF2c to transactivate Rankl 
(A) Putative MEF2 binding sites in the Rankl promoter region of the mouse and other bony vertebrate 
species. (B) Mef2 genes expression in WT osteoblasts (n=3). Expression of each gene is compared to 
the one of Mef2a. (C) Chromatin immunoprecipitation (ChIP) assay in mouse osteoblasts analyzing MEF2 
binding to the Rankl promoter. (D) DNA co-transfection assays in COS cells with a Rankl promoter 
luciferase construct (pRankL-luc) either WT or harboring a mutation in either one of the MEF2 binding 
sites alone or with a MEF2c expression vector. (E) Histomorphometric quantification of the bone surface 
covered by osteoclasts in vertebrae of 2 month-old Mef2afl/fl (n=5), Mef2aosb-/- (n=5), Mef2cfl/fl (n=6) and 
Mef2cosb-/- (n=8) (left panel) mice and long bones of Mef2cfl/fl (n=6) and Mef2cosb-/- (n=8) mice (right 
panel). (F) Serum CTX levels in 2 month-old Mef2afl/fl (n=8), Mef2aosb-/- (n=7), Mef2cfl/fl (n=6) and 
Mef2cosb-/- (n=7) mice. Results are represented as fold changes compared to levels seen in Mef2cfl/fl 
mice. (G) Analysis of Rankl expression in Mef2afl/fl (n=8), Mef2aosb-/- (n=7), Mef2cfl/fl (n=13) and 
Mef2cosb-/- (n=14) mice. Results are expressed as fold changes compared to levels seen in Mef2cfl/fl 
mice. (H) DNA co-transfection assays in COS cells of a Rankl promoter luciferase construct (pRankL-luc) 
either WT or mutant for the MEF2 binding site 1, along with MEF2c and HDAC4 or HDAC5 expression 
vectors. (I) Histomorphometric quantification of the bone surface covered by osteoclasts in the vertebrae 
of 2 month-old control (n=5), Mef2cosb+/- (n=4), Hdac4osb-/- (n=4) and Hdac4osb-/-;Mef2cosb+/- (n=3) mice. 
(J) Analysis of Rankl expression in control (n=6), Mef2cosb+/- (n=3), Hdac4osb-/- (n=4) and Hdac4osb-/-
;Mef2cosb+/- (n=3) calvaria. Results are presented as fold changes compared to levels seen in WT 
osteoblasts. (K) Serum CTX levels of control (n=6), Mef2cosb+/- (n=3), Hdac4osb-/- (n=4) and Hdac4osb-/-
;Mef2cosb+/- (n=3) mice. Results are presented as fold changes compared to levels seen in WT mice. (L) 
Histomorphometric analyses of BV/TV% (percentage of bone volume over trabecular volume) in of 
vertebrae 2 month-old control (n=9), Mef2cosb+/- (n=4), Hdac4osb-/- (n=5) and Hdac4osb-/-;Mef2cosb+/- 
(n=3) mice. Results are given as means ± SEM. *p<0.05 by Student’s test. 
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Figure 3. PTH favors Rankl expression by disrupting the HDAC4-MEF2c interaction. 
(A) DNA transfection assays in ROS17/2.8 cells using a pRankl-luc reporter construct either WT (pRankL-
luc) or mutated for the MEF2 binding site 1 (pRankLs1-luc). Cells were treated with PTH (10nM) or 
vehicle for 16 hours. (B) Western blot analysis of total extracts from osteoblasts treated with vehicle, PTH 
(10nM) or PTH plus bortezomib (25nM) for 2 hours using anti-HDAC4 and anti-βactin antibodies. (C) 
Immunofluorescence showing HDAC4 localization in mouse osteoblasts treated with vehicle or PTH 
(10nM) alone or in the presence of bortezomib (25nM) for 2 hours. (D) Immunofluorescence assays 
showing MEF2C localization in mouse osteoblasts treated with vehicle or PTH (10nM) for 2 hours. (E) 
Immunoprecipitation of HDAC4 in WT osteoblasts treated with vehicle or PTH (10nM) plus bortezomib 
(25nM). Proteins were analyzed by Western Blot using anti-HDAC4 or anti-HDAC4phosphoS246 
antibodies. (F) Analysis of Rankl expression in WT osteoblasts treated with vehicle, PTH (10nM) or PTH 
plus bortezomib (100nM) for 2 hours. Results are presented as fold changes compared to levels seen in 
vehicle treated osteoblasts. (G) Immunoprecipitation of HDAC4 in WT osteoblasts treated with vehicle or 
PTH plus bortezomib (25nM) for 2 hours. Proteins were analyzed by Western Blot using anti-HDAC4 or 
anti-ubiquitin antibodies. (H) Analysis of expression of E3 ubiquitin ligases in WT osteoblasts treated with 
PTH (10nM) for 2 hours. Results for each gene is presented as fold change compared to levels seen in 
vehicle treated osteoblasts. (I) Analysis of Rankl expression in scrambled, Synv1 or Smurf2 siRNA 
transfected osteoblasts. Results are represented as fold changes compared to levels seen in scrambled 
siRNA transfected cells. (J) Analysis of Rankl expression in scrambled, Smurf2 or Synv1 siRNA 
transfected osteoblasts treated with vehicle or PTH (10nM) for 2 hours. Results are represented as fold 
changes compared to levels seen in vehicle treated scrambled siRNA transfected cells. (K) Co-
immunoprecipitation assay in ROS17/2.8 cells showing an interaction between FLAG-Smurf2 and HA-
HDAC4. Cell extracts were immunoprecipitated after 2 hours of treatment with PTH (10nM) or vehicle with 
an anti-FLAG antibody, proteins were detected by Western blot with either anti-HA or anti-FLAG 
antibodies. (L) Analysis of Rankl expression in WT or Ppr+/-;Smurf2+/-  osteoblasts treated with vehicle 
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Figure 4. The sympathetic tone stabilizes HDAC4 to favor Rankl expression 
(A) Analysis of the expression of Hdac4 and Hdac5 in WT osteoblasts treated with vehicle or ISO (10µM) 
for 2 hours. Results are presented as fold changes compared to levels seen in vehicle treated cells. (B) 
Immunofluorescence detection of HDAC4 in WT osteoblasts treated with vehicle or ISO (10µM) for 2 
hours. (C) Co-immunoprecipitation assay in ROS17/2.8 cells showing an interaction between FLAG-ATF4 
and HA-HDAC4/HA-HDAC5. Cell extracts were immunoprecipitated after 2 hours of ISO (10µM) 
treatment with an anti-FLAG antibody, proteins were detected by Western blot with either anti-HA or anti-
FLAG antibodies. The numbers shown under each lane of the top blot represent the fold enhancement in 
the intensity of the bands. (D) Immunoprecipitation of HDAC4 in mouse osteoblasts treated with vehicle 
or ISO (10uM) for 2 hours. Proteins were analyzed by western Blot using either anti-HDAC4 or anti-
HDAC4-S246P antibodies. (E) Serum CTX levels in 2 month-old control (n=8), Hdac4osb+/- (n=3), 
Atf4osb+/- (n=3), and Atf4osb+/-; Hdac4osb+/- (n=3) mice, shown as fold changes compared to levels seen 
in WT mice. (F) Analysis of Rankl expression in long bones of 2 month-old control (n=8), Hdac4osb+/- 
(n=3), Atf4osb+/- (n=3), and Atf4osb+/-; Hdac4osb+/- (n=3) mice. Results are presented as fold changes 
compared to levels seen in WT bones. (G) Histomorphometric quantification of the bone surface covered 
by osteoclasts in vertebrae of 2 month-old control (n=8), Hdac4osb+/- (n=3), Atf4osb+/- (n=3), and Atf4osb+/-
; Hdac4osb+/- (n=3) mice. (H) Co-immunoprecipitation assay in ROS17/2.8 cells showing an interaction 
between FLAG-Runx2 and HA-HDAC4/HDAC5 (left panel). Cell extracts were immunoprecipitated after 4 
hours of ISO (10µM) treatment with an anti-FLAG antibody; proteins were detected by western blot with 
either anti-HA or anti-FLAG antibodies. The numbers shown under each lane of the top blot represent the 
decrease in the intensity of the bands. Immunoprecipitation of Runx2 in mouse osteoblasts treated with 
vehicle or ISO (10uM) for 2 hours (right panel). Proteins were analyzed by western Blot using either anti-
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Figure 5. HDAC4 influences endocrine and cognitive functions of osteoblasts 
(A) Analysis of expression of Osteocalcin and Esp in Hdac4fl/fl (n=11), Hdac4osb-/-(n=11), control (n=8), 
Atf4osb+/- (n=2), Hdac4osb+/- (n=3), Atf4osb+/-;Hdac4osb+/- (n=4), WT (n=8) and Hdac5-/- (n=8) bones.  
Results are presented as fold changes compared to levels seen in bones of Hdac4fl/fl or WT mice. (B) 
Circulating levels of total and undercarboxylated osteocalcin in Hdac4fl/fl (n=11), Hdac4osb-/-(n=11), 
control (n=8), Atf4osb+/- (n=2), Hdac4osb+/- (n=3), Atf4osb+/-;Hdac4osb+/- (n=4), WT (n=8) and Hdac5-/- 
(n=8) mice. (C) Serum insulin levels in Hdac4fl/fl (n=11), Hdac4osb-/-(n=11), WT (n=8) and Hdac5-/- (n=8) 
mice. (D) Serum insulin levels in control (n=8), Atf4osb+/- (n=2), Hdac4osb+/- (n=3), Atf4osb+/-;Hdac4osb+/- 
(n=4) mice. (E) Glucose-stimulated insulin secretion (GSIS) test in 2 month-old Hdac4fl/fl (n=7) and 
Hdac4osb-/- (n=6) mice. (F) Histomorphometric analysis of β-cell area (%) in pancreata of 2 month-old 
Hdac4fl/fl (n=7) and Hdac4osb-/- (n=8) mice. (G) Insulin content in the pancreata of Hdac4fl/fl (n=7) and 
Hdac4osb-/- (n=8) mice. (H-J) Testis size and weight, epididymes and seminal vesicle weights, sperm 
count and testosterone levels in Hdac4osb-/- (n=5-8) and Hdac4fl/fl (n=5-9) mice. (K) Morris water maze 
test performed over 10 days. The graph shows the time (seconds) needed for Hdac4fl/fl (n=8) and 
Hdac4osb-/- (n=9) mice to localize the platform in the swimming area. Results are given as means ± SEM. 
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Figure 6. Model of HDAC4 functions in osteoblasts 
PTH signaling favors HDAC4 (in grey) degradation through polyubiquitination, this releases MEF2c that 
can now transactivate the Rankl promoter and favor bone resorption. On the other hand, following the 
sympathetic tone favors HDAC4 accumulation, its translocation to the nucleus and its association with 
ATF4; this favors Rankl expression and bone resorption as well as Osteocalcin expression and its 
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Figure S1. Related to Figure 1 
 (A) Detection of the deletion allele of Hdac4 by PCR in genomic DNA isolated from tissues of Hdac4osb-/-. 
PCR for GAPDH was used as a loading control. Analysis of the deletion efficiency of the Hdac4 allele with 
the Runx2-cre transgene in Hdac4osb-/-  bone marrow osteoblasts. (B) Analysis of the expression of 
Hdac4 in WT and Hdac5-/- bones (Left) and expression of Hdac5 in Hdac4fl/fl and Hdac4osb-/- bones. 
Results are represented as a fold change compared to levels seen in WT or Hdac4fl/fl bones. (C) 
Analysis of gene expression in Hdac4fl/fl (n=4), Hdac4-/- (n=4), WT, Hdac5-/- bones. Results are shown 
as fold changes compared to levels seen in Hdac4fl/fl bones. Results are given as means ± SEM. 



















































































































































































































































	   61	  
Figure S2. Related to Figure 2 
 (A) Detection of the deleted allele of Mef2a or Mef2c by PCR in genomic DNA isolated from tissues of 
Mef2aosb-/- or Mef2cosb-/- mice.  PCR for GAPDH was used as a loading control. (B) Analysis of the 
deletion efficiency of the Mef2a or Mef2c alleles respectively with the Runx2-cre transgene in Mef2aosb-/- 





































































































































Figure  S2.  Related  to  Figure  2:
(A)  Detection  of   the  mutated  allele  of  Mef2a  or  Mef2c  by  PCR  in  genomic  DNA  isolated  from  tissues  of  
Mef2aosb-­/-­  or  Mef2cosb-­/-­  mice.    PCR  for  gapdh  was  used  as  a  loading  control.  
(B)  Analysis  of  the  deletion  efficiency  of  the  Mef2a    or  Mef2c  alleles  respectively  with  the  Runx2-­cre  trans-­
gene  in  Mef2aosb-­/-­  or  Mef2cosb-­/-­  bone  marrow  osteoblasts.  
Results  are  given  as  means  ±  SEM.  *p<0.05  by  Student’s  test.
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Figure S3. Related to Figure 3 
(A) Analysis of the expression of Hdac4 and Hdac5 in vehicle or PTH (10nM) treated WT osteoblasts. 
Results are represented as a fold change compared to vehicle treated WT osteoblasts. (B) Analysis of the 
expression of E3 ubiquitin ligases in WT osteoblasts treated with ISO (10uM) for 2 hours. Results for 
each gene is presented as fold change compared to levels seen in vehicle treated osteoblasts. (C) 
Analysis of the expression of Smurf2 and Synv1 in primary osteoblasts transfected with either Smurf2 
(left) or Synv1 (right) siRNA. Results are represented as a fold change compared to levels in scrambled 
siRNA transfected cells. (D) Analysis of Hdac4 expression in scrambled, Smurf2 or Synv1 siRNA 
transfected osteoblasts treated with vehicle or PTH (10nM) for 2 hours. Results are represented as fold 
changes compared to levels seen in vehicle treated scrambled siRNA transfected cells. Results are given 













































































































































































































Figure  S3.  Related  to  Figure  3:
(A)  Analysis  of  the  expression  of  Hdac4    and  Hdac5  in  vehicle  or  PTH  (10nM)  treated  WT  osteoblasts  for  2  
hours.  Results  are  represented  as  a  fold  change  compared  to  vehicle  treated  WT  osteoblasts.
(B)  Analysis  of  the  expression  of  E3  ubiquitin  ligases  in  WT  osteoblasts  treated  with  ISO  (10uM)  for  2  hours.  
Results  for  each  gene  is  presented  as  fold  change  compared  to  levels  seen  in  vehicle  treated  osteoblasts.
(C)  Analysis  of  the  expression  of  Smurf2    and  Synv1  in  primary  osteoblasts  transfected  with  either  Smurf2  
(left)  or  Synv1  (right)  siRNA.  Results  are  represented  as  a  fold  change  compared  to  levels  in  scrambled  
siRNA  transfected  cells.    
(D)  Analysis  of  Hdac4  expression   in  scrambled,  Smurf2  or  Synv1  siRNA  transfected  osteoblasts   treated  
with  vehicle  or  PTH  (10nM)  for  2  hours.  Results  are  represented  as  fold  changes  compared  to  levels  seen  
in  vehicle  treated  scrambled  siRNA  transfected  cells.
Results  are  given  as  means  ±  SEM.  *p<0.05  by  Student’s  test.
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Figure S4. Related to Figure 5 
 (A) Insulin tolerance test (ITT) in 2 months-old Hdac4fl/fl and Hdac4osb-/- mice. Results are given as 






































Figure  S4.  Related  to  Figure  5:
(A)  Insulin  tolerance  test  (ITT)  in  2  months-­old  Hdac4fl/fl  and  Hdac4osb-­/-­  mice.  Results  are  given  as  means  
±  SEM.  *p<0.05  by  Student’s  test.
	  













CHAPTER III. GENERAL DISCUSSION  
	  
	   65	  
Both PTH and sympathetic regulation of Rankl expression occur through a cAMP/PKA-dependent 
signaling cascade, for PTH through unidentified transcriptional means and for sympathetic signaling 
through ATF4 (Kondo et al. 2002; Elefteriou et al. 2005). Thus, this study was prompted by the question 
of how PTH and sympathetic signaling regulate Rankl expression through the same second messenger 
via different transcriptional means. We demonstrate here that HDAC4 is an integrator of these two signals 
in osteoblasts. On the one hand, we have shown molecularly and genetically that HDAC4 inhibits MEF2c 
function to transactivate Rankl promoter and PTH disrupts this inhibition by promoting HDAC4 
polyubiquitination. On the other hand, sympathetic signaling promotes HDAC4 accumulation in the 
nucleus and its interaction with ATF4 to promote Rankl expression and thereby bone resorption as well 
as promoting osteoblast endocrine and cognitive functions by favoring osteocalcin expression and 
bioactivity (Figure 6). 
 
The role of class II HDACs in regulation of Rankl expression in osteoblasts 
Given that the overarching goal of this project was to understand how PTH and sympathetic 
signaling promote Rankl expression via different transcriptional means, we turned our attention to class II 
HDACs since this class of regulators has long been thought to connect the extracellular environment to 
the genome of a given cell (Verdin et al. 2003; Haberland et al. 2009). In addition, the regulation of Runx2 
activity by HDAC4 during chondrocyte hypertrophy (Vega et al. 2004) also prompted us to ask whether 
Runx2 functions are also regulated by class II HDACs in osteoblasts. In order to elucidate the functions of 
class II HDACs in osteoblasts, we focused on HDAC4 and HDAC5 since they are the two most highly 
expressed members of this class of HDACs in osteoblasts. The analysis of the mice with the deletion of 
Hdac4 only in osteoblasts and of mice lacking Hdac5 revealed a novel function of these genes in bone 
remodeling. Unlike the expected high bone formation/high bone mass phenotype given that these HDACs 
were regulators of Runx2 in osteoblasts, we observed a high bone resorption/high Rankl phenotype in 
these mice. These results identified these 2 class II HDACs as inhibitors of bone resorption through 
inhibition of Rankl expression in osteoblasts.  
Furthermore, our work on Hdac4 and 5 led us to identify MEF2c as a major regulator of Rankl 
expression in osteoblasts. This finding is not surprising since MEF2 proteins are known to be involved in 
	  
	   66	  
multiple biological processes regulated by class II HDACs (Potthoff and Olson 2007; Haberland et al. 
2009). There are three evidences that allowed us to identify MEF2c as a regulator of Rankl expression. 
First is the presence of three putative MEF2 binding sites within the Rankl promoter region that are 
conserved among various vertebrate species. Second, MEF2c transactivate Rankl promoter through its 
binding to these sites as mutating each of these sites abrogated the ability of MEF2c to transactivate the 
Rankl promoter and also decreased the basal activity of this promoter. Lastly, mice harboring a deletion 
of Mef2c specifically in osteoblasts have a significant decrease in Rankl expression and bone resorption.  
In cell culture experiments both HDAC4 and HDAC5 hamper MEF2c ability to transactivate the 
Rankl promoter, while in vivo the functional interaction between HDAC4 and MEF2c was confirmed as 
Hdac4osb-/- mice lacking one allele of Mef2c in osteoblasts had normal Rankl expression and bone 
resorption parameters. Furthermore, the analysis of Hdac5-/- mice with the deletion of one allele of Mef2c 
specifically in osteoblasts will also confirm genetically the regulation of MEF2c activation of Rankl 
expression by this class II HDAC, therefore also demonstrating in vivo, the importance of both of these 
class II HDACs in regulation of bone resorption through their expression in osteoblasts. 
Identification of this novel function of HDAC4 and HDAC5 in osteoblasts to inhibit 
osteoclastogenesis adds a new depth to the knowledge of the transcriptional control of bone remodeling. 
Given that class II HDACs have been shown to have redundant functions in various tissues (McKinsey et 
al. 2000; Chang et al. 2004), and considering that mice with the deletion of Hdac4 in osteoblasts and 
Hdac5 globally display similar phenotype raises the question of whether the function of these two class II 
HDACs in regulating bone resorption could also be redundant. To answer this question, the analysis of 
the mice that lack Hdac5 as well as Hdac4 specifically in osteoblasts will elucidate further the functions of 
these two proteins in osteoblasts.  
Although we defined the function of MEF2c during osteoclastogenesis, these findings still do not 
exclude the possibility that MEF2c might have other functions in osteoblasts that could be further pursued 
since we only focused on the Rankl expression and bone resorption phenotype of Mef2cosb-/- mice. In 
fact, we noticed that bone formation was also affected in Mef2c-deficient mice, a phenotype we did not 
pursue in this study. A detailed analysis of the bone phenotype of Mef2cosb-/- mice may also add to the 
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knowledge of the function of this family of transcription factors in bone formation and regulation of other 
functions of osteoblasts.  
Another MEF2 family transcription factor that is highly expressed in osteoblasts is Mef2a that also 
transactivates Rankl promoter in vitro, however does not affect Rankl expression and bone resorption 
when deleted specifically in osteoblasts. This also raises the possibility that Mef2a might partially 
compensate for the functions of Mef2c in vivo.  Analysis of mutant mouse line with the deletion of both of 
these genes only in osteoblasts will bring a broader knowledge to the functions of MEF2 family 
transcription factors in regulating osteoblast functions. 
 
PTH regulation of Rankl expression in osteoblasts 
PTH is one of the major endocrine signals regulating Rankl expression in osteoblasts. Although it 
was demonstrated through cell-based assays that CREB is the mediator of this signaling (Fu et al. 2002), 
deletion of Creb specifically in osteoblasts had no effect on Rankl expression or bone resorption 
parameters (Kajimura et al. 2011), thus leaving open the question of how PTH achieves this function in 
osteoblasts. The results presented above as well as the reported regulation of MEF2c functions in chick 
chondrocytes by PTHrP, a molecule showing sequence similarities with PTH (Kozhemyakina et al. 2009), 
prompted us to further test whether PTH is involved in the regulation of HDAC4 -| MEF2c  Rankl 
pathway.  
PTH has a dramatic effect on HDAC4 as it decreases its accumulation in osteoblasts by 
promoting its ubiquitination and degradation. We further demonstrated that PTH-induced ubiquitination of 
HDAC4 occurs, in part, through Smurf2, one of the two E3 ligases among 11 that were tested, whose 
expression is enhanced upon PTH treatment in osteoblasts. Two other lines of evidence suggesting a 
role for Smurf2 in the PTH-induced ubiquitination of HDAC4 is the decrease observed in Rankl 
expression and its further induction with PTH in osteoblasts that lack Smurf2 or one allele of Ppr and one 
allele of Smurf2.   
We are aware, however, that further testing of Smurf2 in this pathway is required to confirm the 
functional relevance of this gene in vivo. In addition to the analysis of the mouse model lacking Smurf2 
specifically in osteoblasts, the analysis of Rankl expression in mice with deletion of one allele of Ppr and 
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one allele of Smurf2 will strengthen the molecular data with genetic evidence to establish the validity of 
the proposed molecular pathway accounting for PTH regulation of Rankl.  
Therefore with the work we present here, we do not only define MEF2c as the first transcription 
factor identified on genetic ground as a mediator of the PTH regulation of Rankl expression but also we 
further provide a mechanism for the regulation of the function of HDAC4 in bone resorption by PTH-
induced ubiquitination in osteoblasts.  
 
Regulation of Rankl expression by sympathetic signaling via HDAC4 
The regulation of HDAC4 by PTH and the notion that class II HDACs connect various 
extracellular cues to the genome of a given cell prompted us to test whether sympathetic signaling, 
another endocrine regulator of Rankl expression (Elefteriou et al. 2005), might recruit HDAC4 for this 
purpose in osteoblasts. It was already known that the sympathetic tone regulates Rankl expression 
through ATF4 (Elefteriou et al. 2005). We show here that sympathetic signaling in osteoblasts achieves 
this function by enhancing Hdac4 and to some extent Hdac5 expression, promoting HDAC4 localization 
to the nucleus and enhancing HDAC4 and HDAC5 interaction with ATF4. We also demonstrate 
genetically that mice with a deletion of one allele of Hdac4 and one allele of Atf4 in osteoblasts display a 
low Rankl/low bone resorption phenotype.  
Molecular data also suggests that the sympathetic regulation of the interaction between these two 
class II HDACs and ATF4 is specific to these two proteins. We demonstrate that the interaction between 
HDAC4/HDAC5 and Runx2 is disrupted by the sympathetic tone. Considering the constant presence of 
catecholamines in a living animal, this provides an explanation for why in the absence of HDAC4 or 
HDAC5, there is no effect on the Runx2-mediated bone formation.  
These findings demonstrate that HDAC4 and ATF4 interaction promotes Rankl expression in 
osteoblasts and that this regulation is dependent on the sympathetic signaling. Further work is needed to 
confirm the validity of such a pathway in vivo. For this purpose, we have started the experiments to test 
the mouse model with deletion of one allele of Adrenergic β2 receptor (Adrβ2) and one allele of Hdac4.  In 
the presence of such functional interaction, we expect that these mice will display a similar phenotype 
than Hdac4osb+/-;Atf4osb+/- mice, i.e., decreased Rankl expression and bone resorption parameters. 
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However, we also do not rule out the possibility that since PTH signaling will still be present in these mice, 
we may not observe a clear phenotype as demonstrated in Hdac4osb+/-;Atf4osb+/- mice. In that case, 
treating osteoblasts that lack one allele of Hdac4 and one allele of Atf4 with ISO and looking at Rankl 
expression will also be instrumental in demonstrating the sympathetic regulation of Rankl expression 
through ATF4 and HDAC4 interaction ex vivo. Given that sympathetic signaling is involved in such 
regulation of Rankl expression, we expect to see a significant decrease in the induction of Rankl 
expression in cells that lack one allele of Hdac4 and one allele of Atf4 compared to that in WT 
osteoblasts. 
Further confirmation of the sympathetic regulation of HDAC4 will ensure that HDAC4 indeed is an 
integrator of PTH and sympathetic signaling in osteoblasts through its interaction with MEF2c for PTH 
and ATF4 for the sympathetic signaling. Although we have identified the transcriptional means of 
regulation of Rankl expression by these two extracellular signals in osteoblasts, further work with the use 
of elaborate proteomics is required to reveal the possible co-regulators that may also play a part in 
regulating the association of HDAC4 with either pathway. Identifying the molecular mechanism of action 
of these two signals in osteoblasts may provide means to develop more effective treatments against 
diseases characterized by increased bone resorption such as osteoporosis (Albright and Reifenstein 
1948; Riggs et al. 1982).  
 
Sympathetic regulation of endocrine functions of bone through HDAC4 
Over the last decade, bone has been shown to be an endocrine organ regulating glucose 
homeostasis, promoting male fertility as well as memory and cognition through the synthesis and 
secretion of the hormone osteocalcin (Karsenty and Ferron ; Oury et al. 2011; Oury et al. 2013b). 
The interaction of ATF4 with HDAC4 and HDAC5, and the regulation of Osteocalcin expression 
by ATF4 (Ducy and Karsenty 1995; Yang et al. 2004) raised the question of whether osteocalcin functions 
might be regulated through the same mechanism.  In addition to the dramatic decrease in osteocalcin 
expression in Hdac4osb-/- mice, the decrease in the circulating levels of total and undercarboxylated 
osteocalcin prompted us to further pursue the phenotype of these mice in more detail.  
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Indeed, Hdac4osb-/- mice display similar defects than those observed in Osteocalcin+/- mice in 
insulin secretion and circulating insulin levels, male fertility and memory and spatial learning (Lee et al. 
2007; Oury et al. 2011; Oury et al. 2013b). That deletion of Hdac5 in mice does not affect Osteocalcin 
expression or its circulating levels suggests that this function of HDAC4 is specific to this class II HDAC 
and that the existence of a specific co-factor associated with HDAC4 but not HDAC5. Thus, proteomic 
and biochemical studies that will need to be used to identify the co-factors associated with HDAC4 
downstream of PTH and sympathetic signaling will also be useful in identifying the different factors that 
promotes this specific function of HDAC4 in regulating osteoblast endocrine and cognitive functions. 
These data altogether suggest that HDAC4 is central to the regulation of osteocalcin functions, 
demonstrating the emerging role of osteoblasts as a multipurpose cell type (Karsenty and Ferron 2012).  
However further confirmation of the regulation of osteocalcin functions through sympathetic 
signaling is needed. Therefore, further experiments are required to assess whether through its regulation 
of the interaction between HDAC4 and ATF4, sympathetic signaling is a regulator of osteocalcin 
functions. To answer this question, we will test the functional interaction between HDAC4 and 
sympathetic signaling in osteoblasts with the use of mouse genetics. Answering this question will not only 
identify a direct link between sympathetic tone and molecular mechanism of regulation of osteocalcin 
functions but will also further add to the existence of the cross-talk between the bone and the whole body, 
defining a second level regulation of Osteocalcin expression and its neuroendocrine functions.  
Finally, these findings also suggest that HDAC4 may be involved in some aspects of aging. The 
abnormalities observed in the absence of osteocalcin with worsened glucose metabolism, decreased 
male fertility, decreased cognition and memory and the decrease in bone mass usually appear as age-
related issues. HDAC4 regulation of these functions presented here suggests a role for this class of 
regulators during aging process and encourages a new way of looking at their regulation and involvement 




	   71	  
CONCLUSION 
Overall, this work showed that the molecular means of PTH regulation of Rankl expression 
occurs through the regulation of MEF2c transactivating function and that PTH achieves this function by 
promoting ubiquitination of HDAC4, in part, via Smurf2. Furthermore, this work provides evidence that 
HDAC4 is indeed an integrator of PTH and sympathetic signaling in the osteoblast. In addition, the 
completion of the suggested experiments that will strengthen the findings of this study will prove again 
that bone is central to the whole body physiology as an endocrine organ by demonstrating a direct link 
between sympathetic signaling and osteocalcin functions via Class II HDAC (Figure 6).  
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